CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

208294Orig1s000

OTHER REVIEW(S)

505(b)(2) ASSESSMENT

Application Information				
NDA # 208294	NDA Supplement #: S-	Efficacy Supplement Type SE-		
Proprietary Name: Beve	espi Aerosphere			
Established/Proper Nam	e: Glycopyrrolate and formote	rol fumarate		
Dosage Form: MDI				
Strengths: 9/4.8 mcg				
Applicant: Pearl Therapeutics				
Date of Receipt: 06/25/2	Date of Receipt: 06/25/2015			
PDUFA Goal Date: 04/25/2016		on Goal Date (if different):		
RPM: Brandi Wheeler				
Proposed Indication(s): COPD				

GENERAL INFORMATION

1) Is this application for a recombinant or biologically-derived product and/or protein or peptide product *OR* is the applicant relying on a recombinant or biologically-derived product and/or protein or peptide product to support approval of the proposed product?

YES	NO	\boxtimes

If "YES "contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

INFORMATION PROVIDED VIA RELIANCE (LISTED DRUG OR LITERATURE)

2) List the information essential to the approval of the proposed drug that is provided by reliance on our previous finding of safety and efficacy for a listed drug, by reliance on published literature, or by reliance on a final OTC monograph. *(If not clearly identified by the applicant, this information can usually be derived from annotated labeling.)*

Varnings and Precautions, Section 5.11
enal Impairment, Section 8.6 Hepatic npairment, 8.7 Renal Impairment linical Pharmacology, Section 12.1 IOA, Section 12.3 PK
Varnings and Precautions, Section 5.11 enal Impairment, Section 8.1 Pregnancy linical Pharmacology, Section 12.3 PK onclinical Toxicology, Section 13.1 arcinogenesis, Mutagenesis, Impairment Fertility

*each source of information should be listed on separate rows, however individual literature articles should not be listed separately

3) The bridge in a 505(b)(2) application is information to demonstrate sufficient similarity between the proposed product and the listed drug(s) or to justify reliance on information described in published literature for approval of the 505(b)(2) product. Describe in detail how the applicant bridged the proposed product to the listed drug(s) and/or published literature¹. See also Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.

Pearl is using the 505(b)(2) pathway in order to rely on the Agency's previous finding of safety for glycopyrrolate including pharmacokinetic (PK) and nonclinical data from studies conducted with the reference listed drug Robinul® Injection (NDA 017558) and published literature on the PK and pharmacology of glycopyrrolate. The Agency agreed that a relative bioavailability assessment for glycopyrrolate was not needed to support a 505(b)(2) application because there were large exposure margins between Bevespi Aerosphere and Robinul Injection.

RELIANCE ON PUBLISHED LITERATURE

4) (a) Regardless of whether the applicant has explicitly stated a reliance on published literature to support their application, is reliance on published literature necessary to support the approval of the proposed drug product (i.e., the application *cannot* be approved as labeled without the published literature)?

YES 🛛 NO 🗌

¹For 505(b)(2) applications that rely on a listed drug(s), bridging studies are often BA/BE studies comparing the proposed product to the listed drug(s). Other examples include: comparative physicochemical tests and bioassay; preclinical data (which may include bridging toxicology studies); pharmacokinetic/pharmacodynamic (PK/PD) data; and clinical data (which may include immunogenicity studies). A bridge may also be a scientific rationale that there is an adequate basis for reliance upon FDA's finding of safety and effectiveness of the listed drug(s) For 505(b)(2) applications that rely upon literature, the bridge is an explanation of how the literature is scientifically sound and relevant to the approval of the proposed 505(b)(2) product

Page 2

If "NO," proceed to question #5.

(b) Does any of the published literature necessary to support approval identify a specific (e.g., brand name) *listed* drug product?

YES		NO	\boxtimes
	-		

If "NO", proceed to question #5. If "YES", list the listed drug(s) identified by name and answer question #4(c).

(c) Are the drug product(s) listed in (b) identified by the applicant	as the	listed drug	g(s)?	
	YES		NO	

¹For 505(b)(2) applications that rely on a listed drug(s), bridging studies are often BA/BE studies comparing the proposed product to the listed drug(s). Other examples include: comparative physicochemical tests and bioassay; preclinical data (which may include bridging toxicology studies); pharmacokinetic/pharmacodynamic (PK/PD) data; and clinical data (which may include immunogenicity studies). A bridge may also be a scientific rationale that there is an adequate basis for reliance upon FDA's finding of safety and effectiveness of the listed drug(s) For 505(b)(2) applications that rely upon literature, the bridge is an explanation of how the literature is scientifically sound and relevant to the approval of the proposed 505(b)(2) product

Page 3

RELIANCE ON LISTED DRUG(S)

Reliance on published literature which identifies a specific approved (listed) drug constitutes reliance on that listed drug. Please answer questions #5-9 accordingly.

5) Regardless of whether the applicant has explicitly cited reliance on listed drug(s), does the application **rely** on the finding of safety and effectiveness for one or more listed drugs (approved drugs) to support the approval of the proposed drug product (i.e., the application cannot be approved without this reliance)?

YES \boxtimes NO \square If "NO," proceed to question #10.

6) Name of listed drug(s) relied upon, and the NDA #(s). Please indicate if the applicant explicitly identified the product as being relied upon (see note below):

Name of Listed Drug	NDA #	Did applicant specify reliance on the product? (Y/N)
Robinul Injection	17558	Yes

Applicants should specify reliance on the 356h, in the cover letter, and/or with their patent certification/statement. If you believe there is reliance on a listed product that has not been explicitly identified as such by the applicant, please contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

7) If this is a (b)(2) supplement to an original (b)(2) application, does the supplement rely upon the same listed drug(s) as the original (b)(2) application?

N/A X YES NO If this application is a (b)(2) supplement to an original (b)(1) application or not a supplemental application, answer "N/A". If "NO", please contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

- 8) Were any of the listed drug(s) relied upon for this application:
 - a) Approved in a 505(b)(2) application?

YES \Box NO \boxtimes If "**YES**", please list which drug(s).

Name of drug(s) approved in a 505(b)(2) application:

b) Approved by the DESI process?

YES NO	\boxtimes
 If " YES ", please list which dru	ıg(s).

Name of drug(s) approved via the DESI process:

c) Described in a final OTC drug monograph?

YES		NO	\boxtimes
If "YES", please	list which	ı drug	(s).

Name of drug(s) described in a final OTC drug monograph:

d) Discontinued from marketing?

YES NO I If "YES", please list which drug(s) and answer question d) i. below. If "NO", proceed to question #9. Name of drug(s) discontinued from marketing: Robinul Injection

i) Were the products discontinued for reasons related to safety or effectiveness? YES NO X (Information regarding whether a drug has been discontinued from marketing for

reasons of safety or effectiveness may be available in the Orange Book. Refer to section 1.11 for an explanation, and section 6.1 for the list of discontinued drugs. If a determination of the reason for discontinuation has not been published in the Federal Register (and noted in the Orange Book), you will need to research the archive file and/or consult with the review team. Do not rely solely on any statements made by the sponsor.)

9) Describe the change from the listed drug(s) relied upon to support this (b)(2) application (for example, "This application provides for a new indication, otitis media" or "This application provides for a change in dosage form, from capsule to solution").

This application provides for a change in dosage form from injection to MDI and for a new indication, COPD.

The purpose of the following two questions is to determine if there is an approved drug product that is equivalent or very similar to the product proposed for approval that should be referenced as a listed drug in the pending application.

The assessment of pharmaceutical equivalence for a recombinant or biologically-derived product and/or protein or peptide product is complex. If you answered **YES to question #1**, proceed to question #12; if you answered **NO to question #1**, proceed to question #10 below.

10) (a) Is there a pharmaceutical equivalent(s) to the product proposed in the 505(b)(2) application that is already approved (via an NDA or ANDA)?

(Pharmaceutical equivalents are drug products in identical dosage forms intended for the same route of administration that: (1) contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified release dosage forms that require a reservoir or overage or such forms as prefilled syringes where residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; (2) do not necessarily contain the same inactive ingredients; and (3) meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates. (21 CFR 320.1(c), FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (the Orange Book)).

Note that for proposed combinations of one or more previously approved drugs, a pharmaceutical equivalent must also be a combination of the same drugs.



If "NO" to (a) proceed to question #11. If "YES" to (a), answer (b) and (c) then proceed to question #12.

(b) Is the pharmaceutical equivalent approved for the same indication for which the 505(b)(2) application is seeking approval?

YES	NO 🗌
-----	------

(c)	Is the listed drug(s) referenced by the application	1 a	phar	maceutical	equival	ent?	
	N/A	1		YES		NO	[

If this application relies only on non product-specific published literature, answer "N/A" If "**YES**" to (c) <u>and</u> there are no additional pharmaceutical equivalents listed, proceed to question #12.

If "**NO**" <u>or</u> if there are additional pharmaceutical equivalents that are not referenced by the application, list the NDA pharmaceutical equivalent(s); you do <u>not</u> have to individually list all of the products approved as ANDAs, but please note below if approved approved generics are listed in the Orange Book. Please also contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

Pharmaceutical equivalent(s):

11) (a) Is there a pharmaceutical alternative(s) already approved (via an NDA or ANDA)?

(Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form or as the same salt or ester. Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times and/or dissolution rates. (21 CFR 320.1(d)) Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate- or standard-release formulations of the same active ingredient.)

Note that for proposed combinations of one or more previously approved drugs, a pharmaceutical alternative must also be a combination of the same drugs.

	YES	S 🗌	NO	\boxtimes
	If "NO", pr	oceed to qı	iestion	#12.
(b) Is the pharmaceutical alternative approved for the same 505(b)(2) application is seeking approval?	e indication f	or which th	ne	
505(0)(2) application is seeking approval.	YE	s 🗌	NO	
(c) Is the approved pharmaceutical alternative(s) reference N/A	as the lister		NO	
If this application relies only on non product-specific publish If " YES " and there are no additional pharmaceutical alternative				on

If "YES" #12.

If "**NO**" <u>or</u> if there are additional pharmaceutical alternatives that are not referenced by the application, list the NDA pharmaceutical alternative(s); you do <u>not</u> have to individually list all

of the products approved as ANDAs, but please note below if approved generics are listed in the Orange Book. Please also contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

Pharmaceutical alternative(s):

PATENT CERTIFICATION/STATEMENTS

12) List the patent numbers of all unexpired patents listed in the Orange Book for the listed drug(s) for which our finding of safety and effectiveness is relied upon to support approval of the (b)(2) product.

Listed drug/Patent number(s):

No patents listed	\boxtimes	proceed to question #14
-------------------	-------------	-------------------------

13) Did the applicant address (with an appropriate certification or statement) all of the unexpired patents listed in the Orange Book for the listed drug(s) relied upon to support approval of the (b)(2) product?

If "NO", list which patents (and which listed drugs) were not addressed by the applicant.

Listed drug/Patent number(s):

- 14) Which of the following patent certifications does the application contain? (*Check all that apply <u>and</u> identify the patents to which each type of certification was made, as appropriate.*)
 - No patent certifications are required (e.g., because application is based solely on published literature that does not cite a specific innovator product)
 - □ 21 CFR 314.50(i)(1)(i)(A)(1): The patent information has not been submitted to FDA. (Paragraph I certification)
 - \square 21 CFR 314.50(i)(1)(i)(A)(2): The patent has expired. (Paragraph II certification)

Patent number(s):

21 CFR 314.50(i)(1)(i)(A)(3): The date on which the patent will expire. (Paragraph III certification)

Patent number(s):

Expiry date(s):

NO

YES

- 21 CFR 314.50(i)(1)(i)(A)(4): The patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the application is submitted. (Paragraph IV certification). *If Paragraph IV certification was submitted, proceed to question #15.*
- 21 CFR 314.50(i)(3): Statement that applicant has a licensing agreement with the

NDA holder/patent owner (must also submit certification under 21 CFR 314.50(i)(1)(i)(A)(4) above). *If the applicant has a licensing agreement with the NDA holder/patent owner, proceed to question #15.*

 \boxtimes 21 CFR 314.50(i)(1)(ii): No relevant patents.

☐ 21 CFR 314.50(i)(1)(iii): The patent on the listed drug is a method of use patent and the labeling for the drug product for which the applicant is seeking approval does not include any indications that are covered by the use patent as described in the corresponding use code in the Orange Book. Applicant must provide a statement that the method of use patent does not claim any of the proposed indications. (Section viii statement)

Patent number(s): Method(s) of Use/Code(s):

- 15) Complete the following checklist *ONLY* for applications containing Paragraph IV certification and/or applications in which the applicant and patent holder have a licensing agreement:
 - (a) Patent number(s):
 - (b) Did the applicant submit a signed certification stating that the NDA holder and patent owner(s) were notified that this b(2) application was filed [21 CFR 314.52(b)]?

YES NO

If "NO", please contact the applicant and request the signed certification.

(c) Did the applicant submit documentation showing that the NDA holder and patent owner(s) received the notification [21 CFR 314.52(e)]? This is generally provided in the form of a registered mail receipt.

YES NO If "NO", please contact the applicant and request the documentation.

(d) What is/are the date(s) on the registered mail receipt(s) (i.e., the date(s) the NDA holder and patent owner(s) received notification):

Date(s):

Note, the date(s) entered should be the date the notification occurred (i.e., delivery date(s)), not the date of the submission in which proof of notification was provided

(e) Has the applicant been sued for patent infringement within 45-days of receipt of the notification listed above?

Note that you may need to call the applicant (after 45 days of receipt of the notification) to verify this information **UNLESS** the applicant provided a written statement from the notified patent owner(s) that it consents to an immediate effective date of approval.

YES NO Patent owner(s) consent(s) to an immediate effective date of approval

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRANDI E WHEELER 04/25/2016

Date	February 26, 2016	
From	Anthony Orencia M.D., F.A.C.P., Janice Pohlman M.D., M.P.H.	
То	Stacy Chin M.D., Anthony Durmowicz M.D., Brandi Wheeler Pharm.D.	
NDA	208294	
Applicant	Pearl Therapeutics, Inc.	
Drug	Glycopyrrolate-formoterol	
NME	No	
Therapeutic	Long acting β-agonist (LABA) and long-acting muscarinic antagonist	
Classification	(LAMA)	
Proposed	^{(b) (4)} COPD	
Indication		
Consultation	September 1, 2015	
Request Date		
Summary Goal	March 25, 2016	
Date		
Action Goal Date	April 25, 2016	
PDUFA Date	April 26, 2016	

1. OVERALL ASSESSMENT OF FINDINGS AND RECOMMENDATIONS

In summary, three clinical studies were submitted in support of the applicant's NDA. Three clinical sites (Drs. Cifuentes, Mirkil and Garver) were selected for audit.

Based on the inspection of three clinical sites and the sponsor, the data reported to the sponsor by these clinical sites and subsequently by the sponsor to the NDA appear to be reliable and may be used in support of the requested indication. The sponsor's oversight of the studies also appears to be adequate.

The preliminary classification for the inspections of Drs. Cifuentes, Mirkil, and Garver, Jr. is No Action Indicated (NAI). The final classification for the sponsor inspection is Voluntary Action Indicated (VAI). Data submitted by the inspected sites appear acceptable and reliable in support of this specific indication. The anonymous complaints and allegations at the sponsor, Drs. Cifuentes and Mirkil study sites were not substantiated during the inspections.

Observations noted above for the three clinical investigator sites are based on communications with the field investigator. An inspection summary addendum will be generated if conclusions change upon receipt and review of the EIR.

2. BACKGROUND

Glycopyrronium is a long acting muscarinic antagonist (LAMA) which exerts its bronchodilatory effect via muscarinic receptors located on smooth muscle cells within the trachea and bronchi. Formoterol fumarate is a long acting beta agonist (LABA). As a bronchodilator, formoterol fumarate stimulates β 2 adrenoreceptors in the airways, inducing airway smooth muscle relaxation.

Three clinical trials were submitted in support of the applicant's NDA 208294, and selected by DPARP for clinical site inspections. In general, these sites enrolled large numbers of subjects and the groups potentially had differential efficacy findings. Additionally, complaints about two of the three clinical investigators (Drs. Cifuentes and Mirkil) and sponsor were received by the Agency.

Study PT003006

Study PT003-006 was a multicenter, randomized, double-blind, parallel group, chronic dosing (24 weeks), placebo- and active-controlled study to assess the efficacy and safety of treatment with glycopyrronium and formoterol fumarate metered dose inhaler (MDI) (GFF MDI, 14.4/9.6 µg exactuator, BID), formoterol fumarate MDI (FF MDI, 9.6 µg ex-actuator, BID), glycopyrronium MDI (GP MDI, 14.4 µg ex-actuator, BID), and tiotropium [Spiriva® (18 µg, open-label, QD)] compared with each other and placebo MDI in subjects with moderate to very severe COPD. The primary objective was to compare the efficacy of GFF MDI to its components on lung function using trough forced expiratory volume in 1 second (FEV1) in subjects with moderate to very severe COPD. For U.S. studies, the primary study efficacy endpoint was the change from baseline in morning pre-dose trough FEV1 at Week #24.

Subjects were screened at 160 sites in the USA, Australia, and New Zealand, The first subject enrolled on Jun 6, 2013 and the last subject completed on Feb 19, 2015. A total of 2054 subjects were planned. A total of 2103 subjects were randomized, of which 2100 subjects were analyzed for safety and 2096 subjects were analyzed for efficacy. Per sponsor's interpretation, efficacy of glycopyrrolate-formoterol fumarate MDI 14.4/9.6 µg, glycopyrrolate MDI 14.4 µg, and formoterol fumarate MDI 9.6 µg as twice-daily treatments for COPD over placebo was demonstrated, using trough forced expiratory volume in 1 second (FEV1) in subjects with moderate to very severe COPD.

Study PT003007

Study PT003007 was a multicenter, randomized, double-blind, parallel group, chronic dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of treatment with glycopyrronium and formoterol fumarate metered dose inhaler (MDI) (GFF MDI, 14.4/9.6 μ g exactuator, BID), formoterol fumarate MDI (FF MDI, 9.6 μ g ex-actuator, BID), and glycopyrronium MDI (GP MDI, 14.4 μ g ex-actuator, twice-daily [BID]) compared with each other and with placebo MDI in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD). The primary objective of this study was to compare the efficacy of GFF MDI to its components on lung function using trough forced expiratory volume in 1 second (FEV1) in

patients with moderate to severe COPD. The primary endpoint was the change from baseline in morning pre-dose trough FEV1 at Week #24.

PT003007 subjects were screened at 140 sites in the USA. The first subject enrolled on July 9, 2013 and the last subject completed on February 25, 2015. A total of 1614 subjects were planned. A total of 1615 subjects were randomized, of which 1610 subjects were analyzed for safety and 1609 subjects were analyzed for efficacy. Per sponsor's interpretation, efficacy of GFF MDI 14.4/9.6 μ g, GP MDI 14.4 μ g, and FF MDI 9.6 μ g as twice-daily treatments for COPD over placebo was demonstrated, using trough forced expiratory volume in 1 second (FEV1) in subjects with moderate to very severe COPD.

Study PT003008

Study PT003008 was a multi-center, randomized, double-blind, parallel group, chronic dosing, active controlled, 28-week safety extension study of the two pivotal 24-week safety and efficacy studies (Studies PT003006 and PT003007). The primary objective of this Phase 3 study is to evaluate the long-term safety and tolerability of glycopyrronium and formoterol fumarate metered dose inhaler (MDI), glycopyrronium MDI, formoterol fumarate MDI and tiotropium (Spiriva®) in subjects with moderate to very severe COPD over 52 weeks.

Study PT003008 was conducted at 205 sites in the United States, Australia, and New Zealand. The first subject enrolled on November 19, 2013 and the last subject completed on December 26, 2014. A total of 850 subjects were planned. Since this was an extension study, 893 subjects who were treated in Study PT003008 were analyzed for efficacy: 583 subjects from Study PT003006 and 309 subjects from Study PT003007. Per sponsor's interpretation, the results of this 28-week extension study to Studies PT003006 and PT003007 demonstrated consistent efficacy of glycopyrrolate-formoterol fumarate MDI 14.4/9.6 µg, glycopyrrolate MDI 14.4 µg, and formoterol fumarate MDI 9.6 µg administered twice daily in subjects with moderate to very severe COPD over 52 weeks.

3. RESULTS (by site):

Name of CI, Address	Site #, Protocol # and # of Subjects	Inspection Date	Classification
Enrique Cifuentes, M.D. Clinical Research Consortium 2727 W. Baseline Rd., Suite 27 Tempe, AZ 85283	Site 6078 Protocol PT003006 Subjects=56 Site 7447 Protocol PT003007 Subjects=40 Site 6078 Protocol PT003008 Subjects=20	October 19 to 23, 2015	Preliminary: NAI

Name of CI, Address	Site #, Protocol # and # of Subjects	Inspection Date	Classification
V. Jerome Mirkil, M.D. 2110 E. Flamingo, Suite 330 Las Vegas, NV 89119	Site 6079 Protocol PT003006 Subjects=43 Site 7450 Protocol PT003007	November 16 to 24, 2015	Preliminary: NAI
Andrew Garver, Jr. M.D. SEC Lung, L.L.C.	Subjects=15 Site 6079 Protocol PT003008 Subjects=16 Site 6021 Protocol PT003006	October 5 to 9, 2015	Preliminary: NAI
822 S. Three Notch St # B Andalusia, AL 36420	Subjects=37		
Pearl Therapeutics, Inc. 280 Headquarters Plaza, East Tower, 2 nd Floor Morristown, N.J. 07969	Sponsor: (1) Protocol PT003006/Randomized Subjects =2103 (2) Protocol PT003007/Randomized Subjects=1615 (3) Protocol (Rollover) PT003008 Subjects=893	October 19 - November 17, 2015	VAI

Key to Compliance Classifications

NAI = No deviation from regulations.

VAI = Deviation(s) from regulations.

OAI = Significant deviations from regulations. Data unreliable.

Pending = Preliminary classification based on information in 483 or preliminary communication with the field; EIR has not been received from the field, and complete review of EIR is pending. Final classification occurs when the post-inspectional letter has been sent to the inspected entity.

<u>Clinical Study Site Investigator</u>

1. Enrique Cifuentes, M.D.

Tempe, AZ 85283

The inspection evaluated the following documents: source records, screening and enrollment logs, case report forms, study drug accountability logs, study monitoring visits, and correspondence. Informed consent documents and sponsor-generated correspondence were also inspected.

The inspection was conducted from October 19 to 23, 2015.

After submission of the NDA, OSI received a complaint from an anonymous source about this site's noncompliance with Good Clinical Practice. Examples cited in the complaint included (subjectively) limited documentation of medical history (for example, not reporting surgical history for subjects with evidence of past surgical procedure on chest X-ray and ensuring that subjects with a history of mental illness were not currently taking concomitant medications for treatment of that illness) and study medication administered outside the protocol-specified window.

For Study PT3006, a total of 83 study subjects were screened, and 56 subjects were enrolled and randomized in the study (Note: 10 study subjects were discontinued from the study; four subjects were lost to follow-up, five subjects refused to continue participation, and one subject had adverse event). Forty six study subjects completed the study. An audit of 20 enrolled subjects' records was conducted.

For Study PT3007, a total of 48 study subjects were screened and 30 subjects were enrolled and randomized in the study (Note: 3 study subjects were lost to follow-up). Twenty seven study subjects completed the study. An audit of 10 enrolled subjects' records was conducted.

For extension (rollover from other trials) Study PT3008, a total of 20 study subjects were screened and 20 subjects were enrolled in the study. Twenty study subjects completed the study. An audit of 10 subjects' records was conducted.

Source documents for all enrolled subjects were reviewed and compared to case report forms and NDA subject line listings. Source documents for the raw data used to assess the primary study endpoint were verifiable at the study site. No under-reporting of serious adverse events was noted. There were no limitations during conduct of the clinical site inspection. The anonymous complaints were not were not substantiated during this site audit.

In general, this clinical site appeared to be in compliance with Good Clinical Practices. A Form FDA 483 (List of Inspectional Observations) was not issued at the end of the inspection.

The study appears to have been conducted adequately, and the data generated by this site appear acceptable and may be used in support of this specific indication.

2. V. Jerome Mirkil, M.D.

Las Vegas, NV 89119

The inspection evaluated the following documents: source records, screening and enrollment logs, case report forms, study drug accountability logs, study monitoring visits, and correspondence. Informed consent documents and sponsor-generated correspondence were also inspected.

The inspection was conducted from November 16 to 24, 2015.

After submission of the NDA, OSI received a complaint from an anonymous source about this site's noncompliance with Good Clinical Practice. Examples cited in the complaint included isolated out of window study drug administration times and performance of ECGs for one subject, isolated failure to report adverse event (hypomagnesemia) that subject was being treated for, and failure to add elevated cholesterol noted on laboratory tests to a subject's medical history.

For Study PT3006, a total of 71 study subjects were screened, and 43 subjects were enrolled and randomized in the study (Note: 10 study subjects were discontinued from the study; 9 study subjects refused to continue participation and one subject had an adverse event). Thirty three study subjects completed the study. An audit of 52 of 71 screened subjects' records was conducted.

For Study PT3007, a total of 27 study subjects were screened and 15 subjects were enrolled and randomized in the study (Note: one subject was lost to follow-up). Fourteen study subjects completed the study. An audit of 21 of the 27 screened subjects' records was conducted.

For <u>extension</u> (rollover from other trials) Study PT3008, a total of 69 study subjects were screened, and 16 subjects were enrolled in the study (Note: one subject withdrew consent). Fifteen study subjects completed the study. An audit of 15 subjects' records was conducted.

Source documents for all enrolled subjects were reviewed and compared to case report forms and NDA subject line listings. Source documents for the raw data used to assess the primary study endpoint were verifiable at the study site. No under-reporting of serious adverse events was noted. There were no limitations during conduct of the clinical site inspection. The anonymous complaints were not considered to be critical and were not substantiated during this site audit.

In general, this clinical site appeared to be in compliance with Good Clinical Practices. A Form FDA 483 (List of Inspectional Observations) was not issued at the end of the inspection.

The study appears to have been conducted adequately, and the data generated by this site appear acceptable and may be used in support of this specific indication.

3. Andrew Garver, Jr. M.D. Andalusia. AL 36420

The inspection evaluated the following documents: source records, screening and enrollment logs, case report forms, study drug accountability logs, study monitoring visits, and correspondence. Informed consent documents and sponsor-generated correspondence were also inspected.

The inspection was conducted from October 5 to 9, 2015.

For Study PT3006, a total of 37 study subjects were screened, and 37 subjects were enrolled, randomized, and completed the study. An audit of 18 enrolled subjects' records was conducted.

Source documents for all enrolled subjects were reviewed and compared to case report forms and NDA subject line listings. Source documents for the raw data used to assess the primary study endpoint were verifiable at the study site. No under-reporting of serious adverse events was noted.

There were no limitations during conduct of the clinical site inspection.

In general, this clinical site appeared to be in compliance with Good Clinical Practices. A Form FDA 483 (List of Inspectional Observations) was not issued at the end of the inspection.

The study appears to have been conducted adequately, and the data generated by this site appear acceptable and may be used in support of this specific indication.

Sponsor inspection

4. Pearl Therapeutics, Inc.

Morristown, NJ 07960

The inspection was conducted from October 19 to November 17, 2015. The inspection evaluated the following: documents related to study monitoring visits and correspondence, Institutional Review Board (IRB) approvals, completed Form FDA 1572s, monitoring reports, drug accountability, and training of staff and site monitors.

Following submission of the NDA OSI received a complaint from an anonymous source of continued sponsor noncompliance with the investigational plan and inadequate monitoring.

A Form FDA 483 was issued at the end of the sponsor inspection for failure to ensure proper monitoring of the study and to ensure the study was conducted in accordance with the investigational plan. Additionally, documentation related to financial disclosure of some investigators and complete investigator statements (Form FDA 1572s) were not obtained prior to enrollment of subjects at some sites.

Examples related to inadequate monitoring and documentation deficiencies include

- 1) The sponsor's monitors did not review the investigator study file as required by the study monitoring plan. Therefore, some documentation, such as required clinical investigator signatures on protocol face sheets were not signed.
- 2) Regulatory deficiencies were found with sponsor oversight of the clinical trial studies.

The Data Monitoring Committee did not comply with the charter, in that further meetings were suspended after the November 20, 2014 meeting.

The DMC charter indicated that the DMC was to hold its last meeting following the database freeze. Following the November 2014 meeting that took place, 47 sites for PT3006, 41 sites for PT-3007, and 56 sites for PT3008 continued to see subjects. The charter-required meeting that was to occur after the database freeze was not convened.

Additionally, charter was signed by the adjudication committee prior to the initiation of the study.

3) The sponsor did not obtain a complete investigator statement form (Form FDA 1572) before permitting a clinical site investigator to participate in a clinical investigation.

Specifically, the sponsor did not ensure that the clinical investigators listed the imaging facility on this investigator statement form for Study PT3006 and extension Study PT3008 involving 139 of 154 clinical sites and for Study PT3007 and extension Study PT3008 involving 119 out of 140 clinical sites. Additionally, the investigator statement form was not completed prior to the site enrolling the first study subject for the following clinical study sites: 00601, 006102, 006090, 006133, and 006126.

The sponsor responded adequately to the List of Inspectional Observations originally on December 4, 2015 and the sponsor's corrective and preventive action plans were presented and were acceptable.

Notwithstanding the above regulatory deficiencies that were not critical, data submitted by this sponsor appear acceptable in support of the requested indication.

{See appended electronic signature page}

Anthony Orencia, M.D. Good Clinical Practice Assessment Branch Division of Clinical Compliance Evaluation Office of Scientific Investigations

CONCURRENCE:

{See appended electronic signature page}

Janice Pohlman, M.D., M.P.H., Team Leader, and for Kassa Ayalew, M.D., M.P.H. Good Clinical Practice Assessment Branch Division of Clinical Compliance Evaluation Office of Scientific Investigations

Central Doc. Rm. Review Division /Division Director/Badrul Chowdhury Review Division /Medical Team Leader/Anthony Durmowicz Review Division /Project Manager/Brandi Wheeler Review Division/MO/Anthony Orencia OSI/Office Director/David Burrow (Acting) OSI/DCCE/ Division Director/Ni Khin OSI/DCCE/Branch Chief/Kassa Ayalew OSI/DCCE/Team Leader/Janice Pohlman/Susan D. Thompson OSI/DCCE/GCP Reviewer/Anthony Orencia OSI/ GCP Program Analyst/Yolanda Patague OSI/Database PM/Dana Walters

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANTHONY J ORENCIA 03/23/2016

JANICE K POHLMAN 03/23/2016 Signing also for Kassa Ayalew, MD, MPH, Branch Chief

Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Medical Policy

PATIENT LABELING REVIEW

Date:	March 11, 2016
To:	Badrul Chowdhury, MD, PhD Director Division of Pulmonary, Allergy, and Rheumatology Products (DPARP)
Through:	LaShawn Griffiths, MSHS-PH, BSN, RN Associate Director for Patient Labeling Division of Medical Policy Programs (DMPP)
	Marcia Williams, PhD Team Leader, Patient Labeling Division of Medical Policy Programs (DMPP)
From:	Nyedra W. Booker, PharmD, MPH Patient Labeling Reviewer Division of Medical Policy Programs (DMPP)
	Meeta Patel, Pharm.D. Regulatory Review Officer Office of Prescription Drug Promotion (OPDP)
Subject:	Review of Patient Labeling: Medication Guide (MG) and Instructions for Use (IFU)
Drug Name (established name):	BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate)
Dosage Form and Route:	inhalation aerosol, for oral inhalation use
Application Type/Number:	NDA 208294
Applicant:	Pearl Therapeutics, Inc.

1 INTRODUCTION

On June 25, 2015, Pearl Therapeutics, Inc. submitted for the Agency's review an original New Drug Application (NDA) 208294 for BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) inhalation aerosol. The proposed indication for BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) is for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

This collaborative review is written by the Division of Medical Policy Programs (DMPP) and the Office of Prescription Drug Promotion (OPDP) in response to a request by the Division of Pulmonary, Allergy, and Rheumatology Products (DPARP) on July 14, 2015 for DMPP and OPDP to review the Applicant's proposed Medication Guide (MG) and Instructions for Use (IFU) for BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) inhalation aerosol.

2 MATERIAL REVIEWED

- Draft BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) MG and IFU received on June 25, 2015, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on March 1, 2016.
- Draft BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) Prescribing Information (PI) received on June 25, 2015, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on March 1, 2016.

3 REVIEW METHODS

To enhance patient comprehension, materials should be written at a 6^{th} to 8^{th} grade reading level, and have a reading ease score of at least 60%. A reading ease score of 60% corresponds to an 8^{th} grade reading level.

Additionally, in 2008 the American Society of Consultant Pharmacists Foundation (ASCP) in collaboration with the American Foundation for the Blind (AFB) published *Guidelines for Prescription Labeling and Consumer Medication Information for People with Vision Loss.* The ASCP and AFB recommended using fonts such as Verdana, Arial or APHont to make medical information more accessible for patients with vision loss. We have reformatted the MG and IFU document using the Arial font, size 10 and 11 respectively.

In our collaborative review of the MG and IFU we have:

- simplified wording and clarified concepts where possible
- ensured that the MG and IFU are consistent with the Prescribing Information (PI)
- removed unnecessary or redundant information
- ensured that the MG and IFU are free of promotional language or suggested revisions to ensure that it is free of promotional language

- ensured that the MG meets the Regulations as specified in 21 CFR 208.20
- ensured that the MG and IFU meet the criteria as specified in FDA's Guidance for Useful Written Consumer Medication Information (published July 2006)

4 CONCLUSIONS

The MG and IFU are acceptable with our recommended changes.

5 RECOMMENDATIONS

- Please send these comments to the Applicant and copy DMPP and OPDP on the correspondence.
- Our collaborative review of the MG and IFU is appended to this memorandum. Consult DMPP and OPDP regarding any additional revisions made to the PI to determine if corresponding revisions need to be made to the MG and IFU.

Please let us know if you have any questions.

26 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NYEDRA W BOOKER 03/11/2016

MEETA N PATEL 03/11/2016

LASHAWN M GRIFFITHS 03/11/2016

Memorandum

	PRE-DECISIONAL AGENCY MEMO
Date:	March 9, 2016
То:	Brandi Wheeler Regulatory Health Project Manager Division of Pulmonary, Allergy, and Rheumatology Products (DPARP)
From:	Meeta Patel, PharmD Regulatory Review Officer Office of Prescription Drug Promotion (OPDP)
Subject:	NDA 208294 OPDP Comments for BEVESPI AEROSPHERE™ (glycopyrrolate and formoterol fumarate) inhalation aerosol, for oral inhalation use, PI, MG, and IFU

OPDP has reviewed the proposed draft PI, received on March 1, 2016, and have the following comments. Comments on the patient labeling will be submitted under a separate cover as a joint review with DMPP.

Thank you for the opportunity to comment on the proposed PI.

If you have any questions or concerns, please contact Meeta Patel at 301-796-4284 or meeta.patel@fda.hhs.gov.

25 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MEETA N PATEL 03/09/2016

LABEL AND LABELING REVIEW

Division of Medication Error Prevention and Analysis (DMEPA) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER)

*** This document contains proprietary information that cannot be released to the public***

Date of This Review:	February 24, 2016
Requesting Office or Division:	Division of Pulmonary, Allergy, and Rheumatology Products (DPARP)
Application Type and Number:	NDA 208294
Product Name and Strength:	Bevespi Aerosphere (Glycopyrrolate and Formoterol Fumarate) Metered Dose Inhaler 9 mcg/4. 8 mcg per inhalation
Product Type:	Drug Device Combination Product
Rx or OTC:	Rx
Applicant/Sponsor Name:	Pearl Therapeutics, Inc.
Submission Date:	June 25, 2015
OSE RCM #:	2015-1581
DMEPA Primary Reviewer:	Lissa C. Owens, PharmD
DMEPA Team Leader (Acting):	Mishale Mistry, PharmD, MPH

1 REASON FOR REVIEW

As part of the evaluation for NDA 208294 submitted on June 25, 2015, DPARP requested DMEPA evaluate the proposed container labels, carton labeling, medication guide and Full Prescribing Information (FPI) for Bevespi Aerosphere for areas of vulnerability that could lead to medication errors.

2 MATERIALS REVIEWED

We considered the materials listed in Table 1 for this review. The Appendices provide the methods and results for each material reviewed.

Table 1. Materials Considered for this Label and Labeling Review		
Material Reviewed	Appendix Section (for Methods and Results)	
Product Information/Prescribing Information	A	
Previous DMEPA Reviews	B-N/A	
Human Factors Study	C-N/A	
ISMP Newsletters	D-N/A	
FDA Adverse Event Reporting System (FAERS)*	E-N/A	
Other	F-N/A	
Labels and Labeling	G	

N/A=not applicable for this review

*We do not typically search FAERS for label and labeling reviews unless we are aware of medication errors through our routine postmarket safety surveillance

3 OVERALL ASSESSMENT OF THE MATERIALS REVIEWED

This is a combination product containing glycopyrrolate and formoterol fumarate. Both glycopyrrolate and formoterol fumarate are currently marketed as single ingredient products or in combination with other ingredients in different dosage forms.

We performed a risk assessment of the proposed container labels, carton labeling, medication guide and full prescribing information to identify deficiencies that may lead to medication errors.

DMEPA finds that the label and labeling can be improved to promote the safe use of the product.

4 CONCLUSION & RECOMMENDATIONS

We recommend that Pearl Therapeutics, Inc. increase the readability and prominence of important information in the proposed labeling to promote the safe use of the product.

4.1 RECOMMENDATIONS FOR PEARL THERAPEUTICS, INC.

We recommend the following be implemented prior to approval of this NDA:

A. All Label and Labeling

1. Revise the presentation of the strength and dosage form so that it is easily recognized:

Bevespi Aerosphere (Glycopyrrolate and Formoterol Fumarate) Inhalation Aerosol 9 mcg/4.8 mcg per inhalation

2. Ensure that the modifier 'Aerosphere' has equal prominence to the root name 'Bevespi'.

B. Carton Labeling

- Relocate 'Shake inhaler well before using' from the side panel to the principal display panel to mitigate the risk that this important information this overlooked. To allow space for this statement, we recommend you consider decreasing the size of the graphics.
- 2. The drug barcode is often used as an additional verification before drug administration in the inpatient setting; therefore, it is an important safety feature that should be part of the label whenever possible. Therefore, we request you add the product barcode to each individual carton as required per 21CFR 201.25(c)(2).

(b) (4)

- 3. Remove the statement
- 4. For consistency with the full Prescribing Information, revise the 'Discard the inhaler...' statement under 'Date foil pouch opened:' to read: Discard the inhaler when the labeled number of inhalations have been used or within 3 months of opening the foil pouch, whichever comes first.'

C. Canister Label

1. Add the lot and expiration date to the canister label.

D. Carton Labeling and Overwrap Foil

1. Revise the usual dosage statement to read: '2 inhalations twice daily'.

APPENDICES: METHODS & RESULTS FOR EACH MATERIALS REVIEWED

APPENDIX A. PRODUCT INFORMATION/PRESCRIBING INFORMATION

Table 2 presents relevant product information for Bevespi Aerosphere that Pearl Therapeutics Inc. submitted on June 25, 2015.

Table 2. Relevant Product Information for Bevespi Aerosphere		
Initial Approval Date	N/A	
Active Ingredient	Glycopyrrolate and Formoterol Fumarate	
Indication	Long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)	
Route of Administration	Oral inhalation	
Dosage Form	Metered Dose Inhaler (MDI)	
Strength	9 mcg/4.8 mcg per inhalation	
Dose and Frequency	2 inhalations twice daily	
How Supplied	Pressurized aluminum canister with an attached dose indicator, a white plastic actuator and mouthpiece, and an orange dust cap	
Storage	Controlled room temperature 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP].	


APPENDIX G. LABELS AND LABELING

G.1 List of Labels and Labeling Reviewed

Using the principles of human factors and Failure Mode and Effects Analysis,¹ along with postmarket medication error data, we reviewed the following Bevespi Aerosphere labels and labeling submitted by Pearl Therapeutics Inc. on June 25, 2015.

- Container label
- Carton labeling
- Instructions for Use (no image)
- Full Prescribing Information (no image)
- Medication Guide (no image)

G.2 Label and Labeling Images



2 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

Canister

¹ Institute for Healthcare Improvement (IHI). Failure Modes and Effects Analysis. Boston. IHI:2004.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LISSA C OWENS 02/24/2016

MISHALE P MISTRY 02/24/2016

Interdisciplinary Review Team for QT Studies Consultation:
Thorough QT Study Review

IND or NDA	NDA 208294	
Brand Name	BEVESPI AEROSPHERE	
Generic Name	Glycopyrronium/Formoterol	
Sponsor	Pearl Therapeutics	
Indication	Long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema	
Dosage Form	Inhaler	
Drug Class	β2-agonist (formoterol fumarate) and anticholinergic (glycopyrrolate)	
Therapeutic Dosing Regimen	Glycopyrronium 18 μg/Formoterol fumarate 9.6 μg administered twice daily	
Duration of Therapeutic Use	Chronic	
Maximum Tolerated Dose	Not identified	
Submission Number and Date	SDN 001/New NDA; 25 Jun 2015	
Review Division	DPARP	

Note: Any text in the review with a light background should be inferred as copied from the sponsor's document.

1 SUMMARY

1.1 OVERALL SUMMARY OF FINDINGS

No significant QTc prolongation effect of glycopyrronium/formoterol (GFF MDI 14.4/9.6 μ g and GFF MDI 115.2/38.4 μ g) was detected in this TQT study. The largest upper bounds of the 2-sided 90% CI for the mean difference between glycopyrronium/formoterol (GFF MDI 14.4/9.6 μ g and GFF MDI 115.2/38.4 μ g) and placebo were below 10 ms, the threshold for regulatory concern as described in ICH E14 guidelines. The largest lower bound of the two-sided 90% CI for the $\Delta\Delta$ QTcI for moxifloxacin was greater than 5 ms, and the moxifloxacin profile over time is adequately demonstrated in Figure 5, indicating that assay sensitivity was established.

In this randomized, blinded, five-period crossover study, 69 healthy subjects received GFF MDI 14.4/9.6 μ g, GFF MDI 115.2/38.4 μ g, GP MDI 115.2 μ g, placebo, and a single oral dose of moxifloxacin 400 mg. Overall summary of findings is presented in Table 1.

Table 1: The Point Estimates and the 90% CIs Corresponding to the Largest Upper Bounds for Glycopyrronium/Formoterol (GFF MDI 14.4/9.6 μg and GFF MDI 115.2/38.4 μg) and the Largest Lower Bound for Moxifloxacin (FDA Analysis)

Treatment	Time (hour)	ΔΔQTcI (ms)	90% CI (ms)
GFF MDI 14.4/9.6 μg	0.17	3.2	(1.3, 5.0)
GFF MDI 115.2/38.4 μg	0.33	7.6	(5.7, 9.5)
GP MDI 115.2 μg	12	0.7	(-1.2, 2.6)
Moxifloxacin 400 mg*	2	9.3	(6.9, 11.7)

* Multiple endpoint adjustment of 3 time points was applied.

For glycopyrronium, the supratherapeutic dose of GFF ($115.2/38.4 \mu g$) produced a mean Cmax value of 60 pg/mL that is 4.9-fold the Cmax at the single therapeutic dose of GFF ($14.4/9.6 \mu g$) and 3.5-fold the steady state Cmax with the proposed therapeutic dose.

For formoterol, 115.2/38.4 μ g-dose produced a mean Cmax that is 3.4 -fold the Cmax at the the single therapeutic dose of GFF (14.4/9.6 μ g) and 2.6-fold the steady state Cmax with the proposed therapeutic dose. Hepatic impairment may decrease formoterol fumarate clearance as it is primarily eliminated via hepatic metabolism. However, exposure data in patients with hepatic or renal impairment are not available. A significant relationship between formoterol fumarate concentrations and $\Delta\Delta$ QTcI was observed. Therefore, a marginal QT prolongation might be expected at the GFF dose of 14.4/9.6 μ g in some hepatic impairment patients.

1.2 QT INTERDISCIPLINARY REVIEW TEAM'S COMMENTS

- Glycopyrronium's QT effect was also evaluated in NDA 207923 and NDA 207930. No significant QT prolongation effect glycopyrrolate at the supratherapeutic dose of 400 μ g (with mean Cmax of 1495 pg/mL) was detected in the TQT study. No evident relationship between glycopyrrolate plasma concentration and $\Delta\Delta$ QTcF was observed.
- A significant relationship between formoterol fumarate concentrations and $\Delta\Delta$ QTcI was observed. The supratherapeutic dose of GFF (115.2/38.4 µg) produced a 2.6-fold margin compared to the therapeutic exposure. Exposure data in patients with hepatic or renal impairment are not available. However, since formoterol fumarate is predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of formoterol fumarate in plasma. Therefore, a marginal QT prolongation might be expected at the GFF dose of 14.4/9.6 µg in some hepatic impairment patients.

2 PROPOSED LABEL

The following is the sponsor's proposed labeling language related to QT.

12.2 Pharmacodynamics

Cardiovascular effects: Healthy Subjects

The potential for QTc interval prolongation was assessed in a double-blind, single-dose, placebo- and positive-controlled crossover trial in 69 healthy subjects. The largest mean (90% upper confidence bound) differences from placebo in baseline-corrected QTcI for 2 inhalations of BEVESPI AEROSPHERE and glycopyrrolate/formoterol fumarate 72/19.2 mcg, were 3.1 (4.7) ms and 7.6 (9.2) ms, respectively, and excluded the clinically relevant threshold of 10 ms.

A dose-dependent increase in heart rate was also observed. The largest mean (90% upper confidence bound) differences from placebo in baseline-corrected heart rate were 3.3 (4.9) beats/min and 7.6 (9.5) beats/min seen within 10 minutes of dosing with 2 inhalations of BEVESPI AEROSPHERE and glycopyrrolate/formoterol fumarate 72/19.2 mcg, respectively.

QT-IRT's proposed labeling language is a suggestion only. We defer final labeling decisions to the Division.

12.2 Pharmacodynamics

Cardiovascular effects: Healthy Subjects

The potential for QTc interval prolongation was assessed in a double-blind, single-dose, placebo- and positive-controlled crossover trial in 69 healthy subjects. The largest mean (90% upper confidence bound) differences from placebo in baseline-corrected QTcI for 2 inhalations of BEVESPI AEROSPHERE and glycopyrrolate/formoterol fumarate 72/19.2 mcg, were 3.1 (4.7) ms and 7.6 (9.2) ms, respectively, and excluded the clinically relevant threshold of 10 ms.

A dose-dependent increase in heart rate was also observed. The largest mean (90% upper confidence bound) differences from placebo in baseline-corrected heart rate were 3.3 (4.9) beats/min and 7.6 (9.5) beats/min seen within 10 minutes of dosing with 2 inhalations of BEVESPI AEROSPHERE and glycopyrrolate/formoterol fumarate 72/19.2 mcg, respectively

3 BACKGROUND

3.1 **PRODUCT INFORMATION**

Glycopyrronium and Formoterol Fumarate (GFF) Inhalation Aerosol (henceforth referred to as Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler [MDI], GFF MDI, or PT003), is a fixed-dose combination of glycopyrrolate (glycopyrronium bromide) 9 μ g and formoterol fumarate 4.8 μ g to be administered via oral inhalation. Glycopyrronium is a long acting muscarinic antagonist (LAMA), and formoterol fumarate is a selective long-acting β 2 antagonist (LABA). GFF MDI is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema at the recommended dose of two inhalations (i.e. 18 μ g of glycopyrrolate [glycopyrronium bromide], equivalent to 14.4 μ g of glycopyrronium, and 9.6 μ g of formoterol fumarate) twice daily (BID).

3.2 MARKET APPROVAL STATUS

GFF is not approved for marketing in any country. Cuvposa (glycopyrrolate) Oral Solution was approved by FDA on 6/28/2010 to treat chronic severe drooling caused by neurologic disorders. Foradil Aerolizer (formoterol fumarate inhalation powder) was approved by FDA in Feb. 2001.

3.3 PRECLINICAL INFORMATION

See Appendix 6.1.

Formoterol fumarate is associated with increased heart rate (HR), maximum rate of rise of left ventricular pressure (dp/dt), pulmonary artery and capillary pressure, coronary blood flow, cardiac output and myocardial oxygen consumption. Decreased peripheral pulmonary and coronary resistances were also observed.

3.4 PREVIOUS CLINICAL EXPERIENCE

Refer QT-IRT consult review (05/03/2012).

Also see Appendix 6.1.

In approved Foradil label, the following QT related languages were included:

5.6 Cardiovascular and Central Nervous System Effects

Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs [*see Overdosage (10)*].

Formoterol fumarate, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of FORADIL AEROLIZER at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, formoterol fumarate, like other sympathomimetic amines, should

be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

12.2 Pharmacodynamics

Systemic Safety and Pharmacokinetic/Pharmacodynamic Relationships

The major adverse effects of inhaled beta₂-agonists occur as a result of excessive activation of the systemic betaadrenergic receptors. The most common adverse effects in adults and adolescents include skeletal muscle tremor and cramps, insomnia, tachycardia, decreases in plasma potassium, and increases in plasma glucose.

Pharmacokinetic/pharmacodynamic (PK/PD) relationships between heart rate, ECG parameters, and serum potassium levels and the urinary excretion of formoterol were evaluated in 10 healthy male volunteers (25 to 45 years of age) following inhalation of single doses containing 12, 24, 48, or 96 mcg of formoterol fumarate. There was a linear relationship between urinary formoterol excretion and decreases in serum potassium, increases in plasma glucose, and increases in heart rate.

In a second study, PK/PD relationships between plasma formoterol levels and pulse rate, ECG parameters, and plasma potassium levels were evaluated in 12 healthy volunteers following inhalation of a single 120 mcg dose of formoterol fumarate (10 times the recommended clinical dose). Reductions of plasma potassium concentration were observed in all subjects. Maximum reductions from baseline ranged from 0.55 to 1.52 mmol/L with a median maximum reduction of 1.01 mmol/L. The formoterol plasma concentration was highly correlated with the reduction in plasma potassium concentration. Generally, the maximum effect on plasma potassium was noted 1 to 3 hours after peak formoterol plasma concentrations were achieved. A mean maximum increase of pulse rate of 26 bpm was observed 6 hours post dose. The maximum increase of mean corrected QT interval (QTc) was 25 msec when calculated using Bazett's correction and was 8 msec when calculated using Fridericia's correction. The QTc returned to baseline within 12-24 hours post-dose. Formoterol plasma concentrations were weakly correlated with pulse rate and increase of QTc duration. The effects on plasma potassium, pulse rate, and QTc interval are known pharmacological effects of this class of study drug and were not unexpected at the very high formoterol dose (120 mcg single dose, 10 times the recommended single dose) tested in this study. These effects were well-tolerated by the healthy volunteers.

The electrocardiographic and cardiovascular effects of FORADIL AEROLIZER were compared with those of albuterol and placebo in two pivotal 12-week double-blind studies of patients with asthma. A subset of patients underwent continuous electrocardiographic monitoring during three 24-hour periods. No important differences in ventricular or supraventricular ectopy between treatment groups were observed. In these two studies, the total number of patients with asthma exposed to any dose of FORADIL AEROLIZER who had continuous electrocardiographic monitoring was about 200.

Continuous electrocardiographic monitoring was performed in an 8-week, randomized, doubleblind, and placebo controlled trial in 204 COPD patients treated with FORADIL AEROLIZER 12 mcg twice daily or placebo. Holter monitoring was used to evaluate predefined proarrhythmic events. Non-sustained ventricular tachycardia occurred in 2 (2.2%) of FORADIL AEROLIZER treated patients compared to none in the placebo group. An increase in ventricular premature beats (VPB) occurred in 3 (3.3 %) of FORADIL AEROLIZER treated patients compared to 2 (1.9%) in the placebo group. There were no events of sustained ventricular tachycardia, ventricular flutter or fibrillation, or symptomatic runs of VPB. One patient in the FORADIL AEROLIZER group had a serious adverse event of atrial flutter. The electrocardiographic effects of FORADIL AEROLIZER were evaluated versus placebo in a 12-month pivotal double-blind study of patients with COPD. An analysis of ECG intervals was performed for patients who participated at study sites in the United States, including 46 patients treated with FORADIL AEROLIZER 12 mcg twice daily, and 50 patients treated with FORADIL AEROLIZER 24 mcg twice daily. ECGs were performed predose, and at 5-15 minutes and 2 hours post-dose at study baseline and after 3, 6 and 12 months of treatment. The results showed that there was no clinically meaningful acute or chronic effect on ECG intervals, including QTc, resulting from treatment with FORADIL AEROLIZER.

3.5 CLINICAL PHARMACOLOGY

Appendix 6.1 summarizes the key features of GFF's clinical pharmacology.

4 SPONSOR'S SUBMISSION

4.1 OVERVIEW

The QT-IRT reviewed the protocol prior to conducting this study under IND 107739. The sponsor submitted the study report PT003009 for glycopyrronium/formoterol, including electronic datasets and waveforms to the ECG warehouse.

4.2 TQT STUDY

4.2.1 Title

A randomized, double-blind, single-dose, five-treatment, cross-over study to assess the cardiovascular safety (including QT/QTc intervals) of two dose levels (one therapeutic and one supra-therapeutic) of glycopyrronium and formoterol fumarate metered dose inhaler (GFF MDI) and a supra-therapeutic dose of glycopyrronium metered dose inhaler (GP MDI) in healthy adult volunteers, compared with moxifloxacin (400 mg open-label) as the positive control

4.2.2 Protocol Number

PT003009

4.2.3 Study Dates

24 Nov 2013 -- 19 Dec 2013

4.2.4 Objectives

Primary objectives:

<u>Safety:</u> To evaluate the effect of a single orally inhaled dose of GFF MDI at two doses and a single orally inhaled dose of GP MDI at a supra-therapeutic dose on the heart rate corrected QT interval (QTc).

Efficacy: This was a cardiac safety study in healthy volunteers; study drug efficacy was not evaluated.

Secondary objectives:

• To establish assay sensitivity by demonstrating the effect of a single oral dose of 400 mg moxifloxacin on QTc.

- To evaluate the effect of a single orally inhaled dose of GFF MDI at two doses(one therapeutic and one supra-therapeutic) and a single orally inhaled dose of GP MDI at a supra-therapeutic dose on heart rate, PR and QRS intervals including outlier analysis and T wave morphology changes.
- To evaluate the safety and tolerability of a single orally inhaled dose of GFF MDI at two doses and a single orally inhaled dose of GP MDI at a supra-therapeutic dose.
- To determine the PK of a single orally inhaled dose of GFF MDI at two doses and the PK of a single orally inhaled dose of GP MDI at a supra-therapeutic dose.
- To determine the relationship between QT/QTc and plasma concentration of glycopyrronium and formoterol following administration of GFF MDI and the relationship between QT/QTc and plasma concentration of glycopyrronium following administration of GP MDI.

4.2.5 Study Description

4.2.5.1 Design

This is a randomized, 10-sequence, crossover design with five dosing occasions. Each dosing occasion was followed by a washout period of at least five days.

4.2.5.2 Controls

The sponsor used both placebo and positive (moxifloxacin) controls.

4.2.5.3 Blinding

The positive (moxifloxacin) control was not blinded, whereas the other treatments were double-blinded.

4.2.6 Treatment Regimen

4.2.6.1 Treatment Arms

There were 5 treatments:

- GFF MDI 14.4/9.6 µg
- GFF MDI 115.2/38.4 µg
- GP MDI 115.2 μg
- Placebo MDI
- Moxifloxacin 400 mg

GFF MDI and GP MDI were designed to be delivered by oral inhalation. The placebo was designed to be delivered by oral inhalation using a MDI. Moxifloxacin 400 mg (one tablet) was administrated orally.

4.2.6.2 Sponsor's Justification for Doses

The thorough QT/QTc study used supratherapeutic doses of 115.2/38.4 μ g GFF MDI (i.e., 115.2 μ g glycopyrronium, equivalent to 144 μ g glycopyrrolate, and 38.4 μ g formoterol) and 115.2 μ g GP MDI (i.e., 115.2 μ g glycopyrronium, equivalent to 144 μ g

glycopyrrolate) in healthy volunteers in order to account for potential accumulation at steady state. Coverage for approximately 2-fold accumulation with formoterol and 4-fold accumulation with glycopyrronium was included based on earlier PK studies.

The doses of glycopyrronium in GFF MDI used in the pharmacokinetic studies were typically higher than the recommended GFF MDI dose of 18/9.6 µg single dose or 36/19.2 µg total daily dose (i.e., 18 µg glycopyrrolate and 9.6 µg formoterol single dose or 36 µg glycopyrrolate and 19.2 µg formoterol total daily dose, equivalent to 14.4 µg glycopyrronium and 9.6 µg formoterol single dose or 36 µg glycopyrronium and 19.2 µg formoterol single dose or 36 µg glycopyrronium and 19.2 µg formoterol single dose or 36 µg glycopyrronium and 19.2 µg formoterol single dose or 36 µg glycopyrronium and 19.2 µg formoterol single dose or 36 µg glycopyrronium and 19.2 µg formoterol total daily dose, respectively). The doses of formoterol used in the Glycopyrronium and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics pharmacokinetic studies were typically within the range of the recommended dose for approved drugs containing formoterol.

Reviewer's Comment:

The doses selected by the sponsor in this study are appropriate. for glycopyrronium, the supratherapeutic dose (115.2/38.4 μ g) produces mean Cmax values 4.9-fold the Cmax at the single therapeutic dose (14.4/9.6 μ g) and 3.5-fold the steady state Cmax at the multiple therapeutic dose.

For formoterol, 115.2/38.4 μ g-dose produced a mean Cmax that is 3.4 -fold the Cmax at the the single therapeutic dose of GFF (14.4/9.6 μ g) and 2.6-fold the steady state Cmax with the proposed therapeutic dose. Hepatic impairment may decrease formoterol fumarate clearance as it is primarily eliminated via hepatic metabolism. However, exposure data in patients with hepatic or renal impairment are not available. A significant relationship between formoterol fumarate concentrations and $\Delta\Delta QTcI$ was observed. Ultimately, the adequacy of the doses will be determined once the effects of all relevant intrinsic and extrinsic factors on the PK of formoterol are known.

4.2.6.3 Instructions with Regard to Meals

Subjects fasted for at least eight hours prior to dosing and for four hours post-dosing in each period. For clinical laboratory assessment blood draws, subjects fasted for at least four hours. Meals during the dosing day of each period were standardized.

The 400 mg moxifloxacin tablet was administered with 250 mL of water. Otherwise, there were no restrictions regarding fluid intake.

Reviewer's Comment: GFF MDI is administered by oral inhalation and the drug absorption is not likely to be influenced by food.

4.2.6.4 ECG and PK Assessments

ECG assessments:

ECG was extracted from continuous 24-hour Holter recordings at predose (-0.75, -0.5 and -0.25 hour), and 2, 6, 10, 20, and 40 minutes and 1, 2, 3, 5, 8, 12, and 24 hours post-dose. During protocol-specified ECG extraction windows, 10 replicates of 14 second digital 12-lead ECG tracings, each recorded after at least a three minute supine rest period were obtained.

PK assessments:

Blood samples for the determination of plasma concentrations of glycopyrronium and formoterol in plasma were collected predose (-1 hour), and at 2, 6, 10, 20, and 40 minutes and 1, 2, 3, 5, 8, 12, and 24 hours post-dose.

Reviewer's Comment: The sponsor's PK and ECG sampling is appropriate for identifying peak glycopyrronium and formoterol *concentrations, and is sufficient to characterize the time-course.*

4.2.6.5 Baseline

The average of predose QT/QTc values on dose administration day of each period was used as baseline for that period.

4.2.7 ECG Collection

Intensive 12-Lead Holter monitoring was used to obtain digital ECGs. Standard 12-Lead ECGs were obtained while subjects were recumbent.

4.2.8 Sponsor's Results

4.2.8.1 Study Subjects

A total of 70 healthy subjects were randomized to the study. Sixty nine subjects received at least one of the five study drugs and all of them were included in the safety analysis set and the PK analysis set. Sixty subjects completed the study.

For the 69 subjects who received treatment with at least one of the five study drugs, the mean age was 31.0 ± 8.0 years (median: 28.0 years) and ranged from 19 to 45 years. Overall, 44 (63.8%) subjects were male and 25 (36.2%) were female.

Fifty-five (79.7%) of the subjects were Black/African American, 11 (15.9%) were White and 3 (4.3%) subjects were documented as "other". Eight (11.6%) subjects were Hispanic or Latino, while the remaining 61 (88.4%) subjects were of some other ethnic origin.

4.2.8.2 Statistical Analyses

4.2.8.2.1 Primary Analysis

The largest LS mean placebo-corrected $\Delta QTcI$ ($\Delta \Delta QTcI$) value following single dose treatment with GFF MDI 115.2/38.4 µg was observed 20 minutes post-dosing and was 7.6 msec with an upper bound of the 90% CI of 9.2 msec. The largest LS mean $\Delta \Delta QTcI$ following single dose administration with GFF MDI 14.4/9.6 µg was observed at approximately 10 minutes post-dosing and was 3.1 msec with an upper bound of the 90% CI value of 4.7 msec. The 90% CI's for $\Delta \Delta QTcI$ for both GFF MDI 14.4/9.6 µg and GP MDI 115.2 µg were below 5 msec at all time points, which is considerably less than the non-inferiority margin of 10 msec. Therefore, it can be concluded that there is no clinically meaningful effect on QT following single dose administration with these treatments.

The sponsor's results for primary analysis are displayed in the following Table 2 and Table 3.

Treatment/Time Point		om Baseline sec)	Estimated Difference from Placebo (msec)		
(hours)	LS Mean	90% CI	LS Mean	90% CI	
	(±SE)	Lower, Upper	(±SE)	Lower, Upper	
GFF MDI 14.4/9.6 µg					
0.03	-3.6 (0.7)	-4.8, -2.4	0.9 (0.9)	-0.6, 2.5	
0.1	1.8 (0.7)	0.6, 3.0	2.5 (0.9)	1.0, 4.0	
0.17	1.7 (0.8)	0.4, 3.0	3.1 (1.0)	1.4, 4.7	
0.33	0.5 (0.7)	-0.7, 1.7	1.5 (0.9)	0.0, 3.1	
0.67	-0.3 (0.8)	-1.6, 1.1	1.1 (1.1)	-0.7, 2.8	
1	-0.8 (0.8)	-2.2, 0.5	1.7 (1.1)	0.0, 3.5	
2	-1.9 (0.8)	-3.1,-0.6	2.4 (1.0)	0.8, 4.0	
3	-1.9 (0.8)	-3.2, -0.5	1.2 (1.0)	-0.5, 3.0	
5	-0.4 (1.2)	-2.5, 1.6	1.3 (1.7)	-1.5, 4.1	
8	-5.4 (1.1)	-7.2,-3.7	1.2 (1.4)	-1.2, 3.5	
12	-3.9 (1.0)	-5.5, -2.4	2.2 (1.3)	0.1, 4.3	
24	-5.7 (1.0)	-7.3, -4.1	0.6 (1.3)	-1.5, 2.7	
GFF MDI 115.2/38.4 µg					
0.03	-2.5 (0.8)	-3.8, -1.3	2.0 (0.9)	0.5, 3.6	
0.1	4.9 (0.7)	3.7, 6.1	5.7 (0.9)	4.1, 7.2	
0.17	5.9 (0.8)	4.6, 7.3	7.3 (1.0)	5.6, 9.0	
0.33	6.6 (0.8)	5.3, 7.9	7.6 (1.0)	6.0, 9.2	
0.67	5.4 (0.8)	4.0, 6.8	6.8 (1.1)	5.0, 8.5	
1	4.0 (0.8)	2.7, 5.4	6.6 (1.1)	4.9, 8.4	
2	3.0 (0.8)	1.7, 4.3	7.3 (1.0)	5.6, 8.9	
3	3.6 (0.8)	2.3, 5.0	6.7 (1.0)	5.0, 8.4	
5	3.0 (1.3)	0.9, 5.1	4.8 (1.7)	2.0, 7.6	

Table 2: Statistical Comparisons of QTcI Change from Baseline over Time by Treatment Group (Sponsor's Results Based on Safety Population)

Treatment/Time Point	· · · · ·	om Baseline sec)	Estimated Difference from Placebo (msec)		
(hours)	LS Mean	90% CI	LS Mean	90% CI	
	(±SE)	Lower, Upper	(±SE)	Lower, Upper	
8	-2.8 (1.1)	-4.6, -1.1	3.7 (1.4)	1.4, 6.1	
12	-2.1 (1.0)	-3.8, -0.5	4.0 (1.3)	1.9, 6.2	
24	-6.4 (1.0)	-8.0, -4.7	-0.1 (1.3)	-2.2, 2.1	
GP MDI 115.2 μg					
0.03	-5.0 (0.7)	-6.2, -3.7	-0.4 (0.9)	-2.0, 1.2	
0.1	-1.0 (0.7)	-2.2, 0.2	-0.3 (0.9)	-1.8, 1.2	
0.17	-1.5 (0.8)	-2.8, -0.2	-0.2 (1.0)	-1.8, 1.5	
0.33	-1.7 (0.8)	-2.9, -0.4	-0.6 (1.0)	-2.2, 0.9	
0.67	-2.3(0.8)	-3.7, -1.0	-1.0 (1.1)	-2.7, 0.8	
1	-3.0(0.8)	-4.4, -1.7	-0.4 (1.1)	-2.2, 1.3	
2	-4.2 (0.8)	-5.4, -2.9	0.1 (1.0)	-1.5, 1.7	
3	-3.5 (0.8)	-4.8, -2.2	-0.4 (1.0)	-2.1, 1.3	
5	-3.3 (1.2)	-5.4, -1.3	-1.6 (1.7)	-4.4, 1.2	
8	-7.8 (1.1)	-9.5, -6.1	-1.2 (1.4)	-3.5, 1.1	
12	-5.3 (1.0)	-6.9, -3.7	0.8 (1.3)	-1.3, 3.0	
24	-7.3 (1.0)	-8.9, -5.7	-1.0 (1.3)	-3.1, 1.2	
Moxifloxacin 400 mg					
0.03	-3.2 (0.7)	-4.5, -2.0	1.3 (0.9)	-0.2, 2.9	
0.1	0.2 (0.7)	-1.0, 1.4	0.9 (0.9)	-0.5, 2.4	
0.17	-0.5 (0.8)	-1.8, 0.8	0.8 (1.0)	-0.8, 2.5	
0.33	-0.6 (0.7)	-1.9, 0.6	0.4 (0.9)	-1.2, 2.0	
0.67	4.9 (0.8)	3.6, 6.3	6.3 (1.1)	4.5, 8.0	
1	5.8 (0.8)	4.4, 7.1	8.3 (1.1)	6.6, 10.1	
2	5.0 (0.8)	3.7, 6.3	9.3 (1.0)	7.7, 10.9	
3	5.6 (0.8)	4.3, 6.9	8.7 (1.0)	7.0, 10.4	
5	3.1 (1.2)	1.1, 5.1	4.8 (1.7)	2.0, 7.6	
8	-0.6 (1.0)	-2.4, 1.1	5.9 (1.4)	3.6, 8.3	
12	-0.2 (1.0)	-1.7, 1.4	6.0 (1.3)	3.9, 8.1	
24	-3.5 (1.0)	-5.1, -1.9	2.8 (1.3)	0.7, 4.9	

 Table 3: Statistical Comparisons of QTcI Change from Baseline over Time

 by Treatment Group (Sponsor's Results Based on Safety Population Continue)

Source: clinical study report PT003009, Table 13, page 62

Reviewer's Comments: please see the reviewer's analysis in section 5.2.

4.2.8.2.2 Assay Sensitivity

Assay sensitivity was confirmed by the QTcI effect that was observed during treatment with moxifloxacin (positive control) with a peak mean $\Delta\Delta$ QTcI of 9.3 msec 2 hours after dosing with the lower bound of the 90% CI above 6 msec at all pre-specified time points (1, 2, and 3 hours post-dosing).

The sponsor's results for assay sensitivity analysis are displayed in the above Table 3.

Reviewer's Comments: please see the reviewer's analysis in section 5.2.

4.2.8.2.3 Categorical Analysis

In terms of the incidence of subjects having absolute category QTcI outlier values, there were no subjects with either a >480 msec or >500 msec outlier value. However, 1 (2%) subject after treatment with GFF MDI 14.4/9.6 μ g, 3 (5%) subjects for GFF MDI 115.2/38.4 μ g, 1 (2%) subject for GP 115.2 μ g, and 1 (2%) subject for moxifloxacin had one or more >450 msec QTcI outlier. No placebo-treated subject had a QTcI outlier in any of the three categories.

In terms of the incidence of subjects having a $\Delta QTcI$ outlier value, there were no subjects with either a $\Delta QTcI$ that was >60 ms or a $\Delta QTcI$ value <60 ms along with a QTcI value <500 ms. However, 2 (3%) subjects after treatment with GFF MDI 115.2/38.4 µg, 2 (3%) subjects for GP 115.2 µg, 2 (3%) subjects for moxifloxacin and 1 (2%) subject for placebo had one or more $\Delta QTcI$ that was >30 ms. No subject after treatment with GFF MDI 14.4/9.6 µg had a $\Delta QTcI$ in any of the three categories.

4.2.8.3 Safety Analysis

No subject after receiving any treatment experienced an SAE and there were no subject deaths for any treatment during the study.


A total of 3 (4.3%) subjects were discontinued due to a TEAE. One subject was discontinued due to atrial fibrillation after receiving GP MDI 115.2 µg, another subject after receiving GFF MDI 14.4/9.6 µg was discontinued due to ECG PR prolongation and a third subject after receiving GFF MDI 115.2/38.4 µg was discontinued due to tremor.

4.2.8.4 Clinical Pharmacology

4.2.8.4.1 Pharmacokinetic Analysis

For glycopyrronium, the supratherapeutic dose of GFF ($115.2/38.4 \mu g$) produces mean Cmax values 4.9-fold the Cmax at the single therapeutic dose ($14.4/9.6 \mu g$) and 3.5-fold the steady state Cmax at multiple therapeutic dose. For formoterol, $115.2/38.4 \mu g$ GFF dose produces Cmax 3.4-fold the Cmax at the single $14.4/9.6 \mu g$ dose and 2.6-fold the steady state Cmax at the multiple $14.4/9.6 \mu g$ dose.

Figure 1: Geometric Mean Plasma Concentration-Time Profile (Linear Scale) of Glycopyrronium and Formoterol (Safety Population)



Source: clinical study report PT003009, Figure 13, page 94

	Glycopyı	rronium PK P	arameters	eters Formoterol PK Parameters			
PK Parameter	GFF MDI 14.4/9.6 μg (N=66)	GFF MDI 115.2/38.4 μg (N=66)	GP MDI 15.2/38.4 μg (N=66)		GFF MDI 115.2/38.4 μg (N=66)		
AUC ₀₋₁₂ (h*pg/mL)	20.79	152.26	183.19	36.29	135.69		
	(122.0)	(65.0)	(74.3)	(55.5)	(45.2)		
AUC _{0-t} (h*pg/mL)	18.61	177.34	226.31	36.39	169.28		
	(151.6)	(81.6)	(88.0)	(72.5)	(50.0)		
AUC _{0-inf} (h*pg/mL)	UC _{0-inf} (h*pg/mL) 29.05		233.11 381.78		205.98		
	(59.2)		(91.5) (87.0)		(49.0)		
AUC _{extr} (%)	33.72	18.55	22.86	21.86	13.03		
	(31.8)	(55.9)	(56.5)	(39.8)	(43.9)		
C _{max} (pg/mL)	12.26	60.30	64.05	9.68	33.63		
	(85.4)	(147.5)	(122.5)	(71.1)	(65.2)		
T _{max} (hours)	0.10	0.10	0.17	0.17	0.17		
λ-z (1/hours)	0.25	0.09	0.06	0.12	0.09		
	(57.4)	(97.3)	(92.4)	(48.9)	(32.5)		
t½ (hours)	2.81	7.73	12.26	5.84	8.17		
	(57.4)	(97.3)	(92.4)	(48.9)	(32.5)		
CL/F (L/hour)	495.73	494.18	301.74	173.14	186.43		
	(59.2)	(91.5)	(87.0)	(46.0)	(49.0)		
Vd/F (L)	2012.41	5509.81	5336.95	1459.82	2196.21		
	(30.0)	(59.0)	(59.6)	(38.0)	(46.9)		


Table 4: GFF MDI Pharmacokinetic Parameters

Source: clinical study report PT003009, Table 25, page 95


4.2.8.4.2 Exposure-Response Analysis


A statistically significant relationship between $\Delta\Delta$ QTcI and formoterol plasma concentrations was demonstrated with a slope of 0.285 ms per pg/mL (90% CI: 0.227; 0.343 pg/mL). The slope for the relationship to glycopyrronium plasma concentrations was shallow and not significant (p=0.3636) (Figure 2). Using this model, a $\Delta\Delta$ QTcI effect of around 9.6 ms (upper bound of 90% CI: 11.2 ms) can be projected at the observed geometric mean formoterol plasma concentration (32.9 pg/mL) after a supratherapeutic dose of 38.4 µg FF. This projected effect is somewhat larger than the observed mean peak $\Delta\Delta$ QTcI effect in the analysis by time point after dosing with GFF MDI 115/38.4 µg. A concentration-dependent, statistically significant, slightly negative relationship was however also noted for the FF-GP interaction, which may indicate coadministration somewhat reduces the $\Delta\Delta$ QTcI effect. The observed data for FF with population mean predictions are provided in Figure 3 for subjects who received either the therapeutic or supra-therapeutic dose of GFF MDI.





Source: clinical study report PT003009, Figure 15, page 99





Source: clinical study report PT003009, Figure 14, page 98

Reviewer's Analysis: We will provide our independent analysis results in Section 5.2. Our analyses results are similar to those provided by the sponsor.

5 REVIEWERS' ASSESSMENT

5.1 EVALUATION OF THE QT/RR CORRECTION METHOD

We evaluated the appropriateness of the correction methods (QTcF and QTcI). Baseline values were excluded in the validation. Ideally, a good correction QTc would result in no relationship of QTc and RR intervals.

We used the criterion of Mean Sum of Squared Slopes (MSSS) from individual regressions of QTc versus RR. The smaller this value is, the better the correction. Based on the results listed in Table 5, it appears that QTcF and QTcI correct QT almost equally well. Therefore, this statistical reviewer used QTcI for the primary statistical analysis.

Correctionivictitous							
	QTcF	QTcI					
Ν	MSSS	Ν	MSSS				
63	0.00144	63	0.00182				
67	0.00219	67	0.00199				
66	0.00233	66	0.00235				
64	0.00300	64	0.00398				
65	0.00138	65	0.00143				
69	0.00090	69	0.00091				
	N 63 67 66 64 65	630.00144670.00219660.00233640.00300650.00138	N MSSS N 63 0.00144 63 67 0.00219 67 66 0.00233 66 64 0.00300 64 65 0.00138 65				

 Table 5: Average of Sum of Squared Slopes for Different QT-RR

 CorrectionMethods

The relationship between different correction methods and RR is presented in Figure 4.




Figure 4: QT, QTcB, QTcF, and QTcI vs. RR (Each Subject's Data Points are Connected with a Line)

5.2 STATISTICAL ASSESSMENTS

5.2.1 QTc Analysis

5.2.1.1 The Primary Analysis for Glycopyrronium/Formoterol

The statistical reviewer used mixed model to analyze the \triangle QTcI effect. The model includes treatment, time point, sequence, period, and treatment by time point as fixed effects and subject as a random effect. Baseline values are also included in the model as a covariate. The analysis results are listed in the following tables.

	14.4/9.6 μg									
	ΔQTcI (ms) GFF MDI 14.4/ 9.6 μg	ΔQTcI (ms) Placebo	ΔΔQTcI (ms) GFF MDI 14.4/ 9.6 μg							
Time (hour)	LSmean	LSmean LSmean		90% CI						
0.03	-3.5	-4.4	1.0	(-0.8, 2.9)						
0.1	2.0	-0.5	2.5	(0.7, 4.4)						
0.17	1.9	-1.2	3.2	(1.3, 5.0)						
0.33	0.7	-0.9	1.6	(-0.3, 3.4)						
0.67	-0.1	-1.2	1.2	(-0.7, 3.0)						
1	-0.6	-2.4	1.8	(-0.0, 3.7)						
2	-1.6	-4.1	2.5	(0.6, 4.3)						
3	-1.7	-2.9	1.4	(-0.5, 3.3)						
5	-0.2	-1.5	1.5	(-0.4, 3.4)						
8	-5.3	-6.5	1.3	(-0.6, 3.2)						
12	-3.8	-6.0	2.3	(0.4, 4.1)						
24	-5.6	-6.0	0.6	(-1.2, 2.5)						

Table 6: Analysis Results of \triangle QTcI and $\triangle \triangle$ QTcI for Treatment Group = GFF MDI 14.4/9.6 µg

Table 7: Analysis Results of $\triangle QTcI$ and $\triangle \Delta QTcI$ for Treatment Group = GFF MDI
115.2/38.4 µg

	ΔQTcI (ms) GFF MDI 115.2/ 38.4 μg	ΔQTcI (ms) Placebo	ΔΔQTcI (ms) GFF MDI 115.2/ 38.4 μg		
Time (hour)	LSmean	LSmean	LSmean	90% CI	
0.03	-2.6	-4.4	2.1	(0.2, 4.0)	
0.1	4.9	-0.5	5.7	(3.8, 7.6)	
0.17	5.9	-1.2	7.4	(5.5, 9.3)	
0.33	6.3	-0.9	7.6	(5.7, 9.5)	
0.67	5.4	-1.2	6.9	(5.0, 8.8)	
1	4.0	-2.4	6.8	(4.9, 8.7)	
2	3.0	-4.1	7.3	(5.4, 9.2)	
3	3.5	-2.9	6.8	(4.9, 8.7)	

	ΔQTcI (ms) GFF MDI 115.2/ 38.4 μg	ΔQTcI (ms) Placebo	ΔΔQTcI (ms) GFF MDI 115.2/ 38.4 μg		
Time (hour)	LSmean	LSmean	LSmean	90% CI	
5	2.7	-1.5	4.8	(2.9, 6.7)	
8	-2.8	-6.5	4.0	(2.1, 5.9)	
12	-2.1	-6.0	4.1	(2.2, 6.0)	
24	-6.3	-6.0	-0.1	(-2.0, 1.8)	

Table 8: Analysis Results of $\triangle QTcI$ and $\triangle \Delta QTcI$ for Treatment Group = GP MDI 115.2 µg

	ΔQTcI (ms) GFF MDI 115.2/ 38.4 μg	ΔQTcI (ms) Placebo	GFF N	TcI (ms) /IDI 115.2/ 8.4 μg
Time (hour)	LSmean	LSmean	LSmean	90% CI
0.03	-5.0	-4.4	-0.5	(-2.4, 1.4)
0.1	-1.1	-0.5	-0.4	(-2.3, 1.5)
0.17	-1.5	-1.2	-0.2	(-2.1, 1.6)
0.33	-1.8	-0.9	-0.8	(-2.7, 1.1)
0.67	-2.4	-1.2	-1.1	(-3.0, 0.8)
1	-3.0	-2.4	-0.5	(-2.4, 1.4)
2	-4.2	-4.1	-0.0	(-1.9, 1.9)
3	-3.6	-2.9	-0.6	(-2.4, 1.3)
5	-3.3	-1.5	-1.7	(-3.6, 0.2)
8	-7.8	-6.5	-1.3	(-3.1, 0.6)
12	-5.4	-6.0	0.7	(-1.2, 2.6)
24	-7.6	-6.0	-1.3	(-3.2, 0.6)

The largest upper bounds of the 2-sided 90% CI for the mean differences between GFFMDI 14.4/9.6 μ g and placebo, and between GFF MDI 115.2/38.4 μ g and placebo were 5.0 ms and 9.5 ms, respectively.

5.2.1.2 Assay Sensitivity Analysis

The statistical reviewer used the same statistical model to analyze moxifloxacin and placebo data. The results are presented in Table 9. The largest unadjusted 90% lower confidence interval was 7.4 ms. By considering Bonferroni multiple endpoint adjustment, the largest lower confidence interval was 6.9 ms, which indicates that an at least 5 ms QTcI effect due to moxifloxacin can be detected from the study.

	ΔQTcI (ms) Moxifloxacin 400 mg	ΔQTcI (ms) Placebo) ΔΔQTcI (ms) Moxifloxacin 400 mg			
Time (hour)	LSmean	LSmean	LSmean	90% CI	Adjust 90% CI*	
0.03	-3.2	-4.4	1.3	(-0.6, 3.2)	(-1.1, 3.8)	
0.1	0.0	-0.5	0.7	(-1.1, 2.6)	(-1.7, 3.2)	
0.17	-0.6	-1.2	0.7	(-1.2, 2.6)	(-1.7, 3.1)	
0.33	-0.5	-0.9	0.5	(-1.4, 2.4)	(-1.9, 3.0)	
0.67	4.9	-1.2	6.3	(4.5, 8.2)	(3.9, 8.8)	
1	5.7	-2.4	8.3	(6.5, 10.2)	(5.9, 10.8)	
2	5.1	-4.1	9.3	(7.4, 11.2)	(6.9, 11.7)	
3	5.5	-2.9	8.7	(6.9, 10.6)	(6.3, 11.2)	
5	3.0	-1.5	4.9	(3.0, 6.7)	(2.4, 7.3)	
8	-0.7	-6.5	6.1	(4.3, 8.0)	(3.7, 8.6)	
12	-0.1	-6.0	6.1	(4.2, 8.0)	(3.7, 8.5)	
24	-3.3	-6.0	2.9	(1.0, 4.8)	(0.4, 5.3)	

Table 9: Analysis Results of $\triangle QTcI$ and $\triangle \Delta QTcI$ for Moxifloxacin

* Bonferroni method was applied for multiple endpoint adjustment for 3 time points.

5.2.1.3 Graph of ΔΔQTcI Over Time

The following figure displays the time profile of $\Delta\Delta$ QTcI for different treatment groups. (Note: CIs are all unadjusted including moxifloxacin)




Figure 5: Mean and 90% CI △△QTcI Timecourse

5.2.1.4 Categorical Analysis

Table 10 lists the number of subjects as well as the number of observations whose QTcI values were \leq 450 ms and between 450 ms and 480 ms. No subject's QTcI was above 480 ms.

	Total N		QTcI<	≔450 ms	450 <qtci<=480 ms<="" th=""></qtci<=480>	
Treatment Group	Subj. #	Obs. #	Subj. #	Obs. #	Subj. #	Obs. #
Baseline	69	968	69 (100%)	968 (100%)	0 (0.0%)	0 (0.0%)
Placebo MDI	63	752	63 (100%)	752 (100%)	0 (0.0%)	0 (0.0%)
Moxifloxacin 400 mg	67	787	66 (98.5%)	786 (99.9%)	1 (1.5%)	1 (0.1%)
GFF MDI 14.4/9.6 µg	66	786	65 (98.5%)	785 (99.9%)	1 (1.5%)	1 (0.1%)
GFF MDI 115.2/38.4 μg	64	749	61 (95.3%)	744 (99.3%)	3 (4.7%)	5 (0.7%)
GP MDI 115.2 μg	65	777	64 (98.5%)	776 (99.9%)	1 (1.5%)	1 (0.1%)

Table 10: Categorical Analysis for QTcI

Table 11 lists the categorical analysis results for Δ QTcI. No subject's change from baseline in QTcI was above 60 ms.

	Total N ΔQTcI<=30 ms		30<ΔQTcI<=60 ms						
Treatment Group	Subj. #	Obs. #	Subj. #	Obs. #	Subj. #	Obs. #			
Placebo MDI	63	752	61 (96.8%)	750 (99.7%)	2 (3.2%)	2 (0.3%)			
Moxifloxacin 400 mg	67	787	65 (97.0%)	785 (99.7%)	2 (3.0%)	2 (0.3%)			
GFF MDI 14.4/9.6 μg	66	786	66 (100%)	786 (100%)	0 (0.0%)	0 (0.0%)			
GFF MDI 115.2/38.4 μg	63	744	61 (96.8%)	740 (99.5%)	2 (3.2%)	4 (0.5%)			
GP MDI 115.2 μg	65	777	63 (96.9%)	775 (99.7%)	2 (3.1%)	2 (0.3%)			

Table 11: Categorical Analysis of AQTcI

5.2.2 HR Analysis

The same statistical analysis was performed based on HR. The point estimates and the 90% confidence intervals are presented in Table 12. The largest upper limits of 90% CI for the HR mean differences between GFFMDI 14.4/9.6 μ g and placebo and GFF MDI 115.2/38.4 μ g and placebo were 5.0 bpm and 8.6 bpm, respectively.

The outlier analysis results for HR are presented in Table 13.

		GFF MDI 14.4/ 9.6 μg			GFF MDI 115.2/ 38.4 μg		GP MDI 115.2 μg	
		ΔHR (bpm)	ДДНR (bpm)	ΔHR (bpm)	ΔΔHR (bpm)	ΔHR (bpm)	ΔΔHR (bpm)	
Time (hour)	ΔHR (bpm) Placebo	LSmean	LSmean (90% CI)	LSmean	LSmean (90% CI)	LSmean	LSmean (90% CI)	
0.03	5.6	6.7	1.5 (0.0, 3.0)	9.2	3.8 (2.2, 5.3)	6.2	0.9 (-0.6, 2.4)	
0.1	1.1	4.1	3.5 (2.0, 5.0)	7.8	6.8 (5.3, 8.3)	1.6	0.8 (-0.7, 2.3)	
0.17	1.2	4.0	3.1 (1.7, 4.6)	8.3	7.0 (5.5, 8.5)	1.3	0.3 (-1.2, 1.8)	
0.33	1.0	3.4	2.8 (1.4, 4.3)	6.4	5.5 (3.9, 7.0)	0.8	0.1 (-1.4, 1.6)	
0.67	0.4	2.5	2.5 (1.0, 4.0)	7.0	6.7 (5.2, 8.2)	1.0	0.8 (-0.7, 2.3)	
1	0.7	3.1	2.9 (1.4, 4.3)	7.6	7.0 (5.5, 8.6)	1.2	0.7 (-0.8, 2.2)	
2	1.9	3.2	1.7 (0.2, 3.2)	8.1	6.2 (4.7, 7.7)	0.4	-1.3 (-2.8, 0.2)	
3	0.6	2.0	1.8 (0.3, 3.3)	6.1	5.6 (4.1, 7.1)	-0.2	-0.5 (-2.0, 1.0)	
5	11.1	11.4	0.7 (-0.8, 2.1)	14.0	3.3 (1.8, 4.8)	9.0	-1.8 (-3.3, -0.3)	
8	10.2	9.5	-0.3 (-1.8, 1.2)	13.3	3.2 (1.7, 4.7)	7.5	-2.4 (-3.9, -1.0)	
12	8.0	8.2	0.7 (-0.8, 2.2)	10.3	2.5 (0.9, 4.0)	6.1	-1.6 (-3.1, -0.1)	
24	9.6	10.7	1.6 (0.1, 3.0)	12.4	2.9 (1.4, 4.4)	9.6	0.2 (-1.2, 1.7)	

Table 12: Analysis Results of ΔHR and $\Delta \Delta HR$

Table 13: Categorical Analysis for HR

	Total N	HR<=100 bpm	HR>100 bpm	HR>45 bpm	HR<=45 bpm
Treatment Group	Subj. #	Subj. #	Subj. #	Subj. #	Subj. #
Baseline	69	69 (100%)	0 (0.0%)	65 (94.2%)	4 (5.8%)
Placebo MDI	63	61 (96.8%)	2 (3.2%)	61 (96.8%)	2 (3.2%)
Moxifloxacin 400 mg	67	64 (95.5%)	3 (4.5%)	66 (98.5%)	1 (1.5%)
GFF MDI 14.4/9.6 μg	66	66 (100%)	0 (0.0%)	66 (100%)	0 (0.0%)
GFF MDI 115.2/38.4 μg	66	64 (97.0%)	2 (3.0%)	66 (100%)	0 (0.0%)
GP MDI 115.2 μg	66	65 (98.5%)	1 (1.5%)	65 (98.5%)	1 (1.5%)

5.2.3 PR Analysis

Similar statistical analysis was performed based on PR interval. The point estimates and the 90% confidence intervals are presented in Table 14. The largest upper limits of 90% CI for the PR mean differences between GFFMDI 14.4/9.6 μ g and placebo and GFF MDI 115.2/38.4 μ g and placebo were 3.1 ms and 2.7 ms, respectively.

The outlier analysis results for PR are presented in Table 15.

Table 14: Analysis Results of DPR and DDPR							
		GFF MDI 14.4/ 9.6 μg		GFF MDI 115.2/ 38.4 μg		GP MDI 115.2 μg	
		ΔPR (ms)	ΔΔPR (ms)	ΔPR (ms)	ΔΔPR (ms)	ΔPR (ms)	ΔΔPR (ms)
Time (hour)	ΔPR (ms) Placebo	LSmean	LSmean (90% CI)	LSmean	LSmean (90% CI)	LSmean	LSmean (90% CI)
0.03	-5.7	-6.0	-0.3 (-2.6, 2.0)	-5.8	0.0 (-2.2, 2.3)	-5.5	-0.0 (-2.3, 2.2)
0.1	-2.9	-4.2	-1.4 (-3.6, 0.9)	-7.3	-4.3 (-6.6, -2.0)	-2.9	-0.3 (-2.5, 2.0)
0.17	-3.0	-3.5	-0.6 (-2.8, 1.7)	-8.4	-5.3 (-7.6, -3.0)	-1.5	1.3 (-0.9, 3.6)
0.33	-2.0	-3.8	-1.8 (-4.0, 0.5)	-8.7	-6.6 (-8.9, -4.4)	-0.3	1.5 (-0.8, 3.8)
0.67	-1.7	-2.8	-1.1 (-3.3, 1.2)	-6.8	-5.0 (-7.2, -2.7)	-0.9	0.7 (-1.6, 2.9)
1	-0.7	-2.6	-2.0 (-4.2, 0.3)	-5.9	-5.1 (-7.4, -2.8)	-0.0	0.5 (-1.8, 2.7)
2	0.3	0.5	0.2 (-2.1, 2.4)	-3.6	-3.7 (-6.0, -1.5)	0.8	0.3 (-2.0, 2.6)
3	-3.4	-4.7	-1.5 (-3.7, 0.8)	-7.2	-3.7 (-6.0, -1.4)	-3.6	-0.4 (-2.6, 1.9)
5	-8.7	-8.4	0.2 (-2.1, 2.4)	-10.9	-2.1 (-4.4, 0.2)	-8.6	-0.1 (-2.4, 2.1)
8	-9.1	-8.8	0.1 (-2.2, 2.3)	-9.9	-0.7 (-3.0, 1.6)	-7.3	1.6 (-0.7, 3.9)
12	-8.9	-10.3	-1.4 (-3.6, 0.8)	-8.4	0.4 (-1.9, 2.7)	-7.6	1.1 (-1.2, 3.4)
24	-3.0	-2.1	0.9 (-1.4, 3.1)	-4.0	-0.8 (-3.1, 1.4)	-3.1	-0.3 (-2.6, 2.0)

Table 14: Analysis Results of $\triangle PR$ and $\triangle \triangle PR$

	Total N		PR<=200 ms		PR>200 ms	
Treatment Group	Subj. #	Obs. #	Subj. #	Obs. #	Subj. #	Obs. #
Baseline	68	953	62 (91.2%)	917 (96.2%)	6 (8.8%)	36 (3.8%)
Placebo MDI	63	746	59 (93.7%)	741 (99.3%)	4 (6.3%)	5 (0.7%)
Moxifloxacin 400 mg	67	784	63 (94.0%)	763 (97.3%)	4 (6.0%)	21 (2.7%)
GFF MDI 14.4/9.6 μg	66	778	61 (92.4%)	757 (97.3%)	5 (7.6%)	21 (2.7%)
GFF MDI 115.2/38.4 μg	66	748	63 (95.5%)	741 (99.1%)	3 (4.5%)	7 (0.9%)
GP MDI 115.2 μg	66	773	62 (93.9%)	760 (98.3%)	4 (6.1%)	13 (1.7%)

Table 15: Categorical Analysis for PR

5.2.4 QRS Analysis

Similar statistical analysis was performed based on QRS interval. The point estimates and the 90% confidence intervals are presented in Table 16. The largest upper limits of 90% CI for the QRS mean differences between GFFMDI 14.4/9.6 μ g and placebo and GFF MDI 115.2/38.4 μ g and placebo were 0.8 ms and 1.4 ms, respectively.

The outlier analysis results for QRS are presented in Table 17.

GFF MDI 14.4/ 9.6 μg				MDI 115.2/ 38.4 μg	GP MDI 115.2 μg		
		ΔQRS (ms)	ΔΔQRS (ms)	ΔQRS (ms)	ΔΔQRS (ms)	ΔQRS (ms)	ΔΔQRS (ms)
Time (hour)	ΔQRS (ms) Placebo	LSmean	LSmean (90% CI)	LSmean	LSmean (90% CI)	LSmean	LSmean (90% CI)
0.03	-0.2	-0.0	0.2 (-0.3, 0.7)	-0.2	-0.0 (-0.6, 0.5)	-0.1	0.1 (-0.5, 0.6)
0.1	-0.1	0.2	0.3 (-0.2, 0.8)	0.1	0.2 (-0.3, 0.7)	0.0	0.1 (-0.4, 0.6)
0.17	0.0	0.1	0.1 (-0.4, 0.6)	0.2	0.1 (-0.4, 0.6)	0.0	0.0 (-0.5, 0.5)
0.33	-0.0	0.2	0.2 (-0.3, 0.7)	0.4	0.4 (-0.1, 0.9)	0.1	0.2 (-0.3, 0.7)
0.67	0.0	0.2	0.2 (-0.3, 0.7)	0.7	0.6 (0.1, 1.1)	0.2	0.2 (-0.3, 0.7)
1	-0.0	0.2	0.2 (-0.3, 0.7)	0.8	0.7 (0.2, 1.3)	0.2	0.3 (-0.2, 0.8)
2	-3.3	-3.1	0.2 (-0.3, 0.7)	-2.4	0.9 (0.4, 1.4)	-3.4	-0.0 (-0.5, 0.5)
3	0.1	0.3	0.2 (-0.3, 0.7)	0.5	0.4 (-0.1, 0.9)	0.2	0.2 (-0.3, 0.7)
5	0.6	0.9	0.2 (-0.3, 0.7)	1.1	0.4 (-0.1, 0.9)	0.6	-0.1 (-0.6, 0.4)
8	-3.8	-3.9	-0.1 (-0.6, 0.4)	-3.9	-0.1 (-0.6, 0.4)	-4.0	-0.2 (-0.7, 0.3)
12	-0.1	0.1	0.2 (-0.3, 0.7)	0.1	0.2 (-0.3, 0.8)	-0.0	0.1 (-0.4, 0.6)
24	-3.3	-3.3	0.0 (-0.5, 0.5)	-3.2	0.0 (-0.5, 0.6)	-3.3	0.0 (-0.5, 0.5)

Table 16: Analysis Results of $\triangle QRS$ and $\triangle \triangle QRS$

Table 17: Categorical Analysis for QRS

	Total N		QRS<=110 ms		QRS>110 ms	
Treatment Group	Subj. #	Obs. #	Subj. #	Obs. #	Subj. #	Obs. #
Baseline	69	968	56 (81.2%)	852 (88.0%)	13 (18.8%)	116 (12.0%)
Placebo MDI	63	753	53 (84.1%)	682 (90.6%)	10 (15.9%)	71 (9.4%)
Moxifloxacin 400 mg	67	793	53 (79.1%)	693 (87.4%)	14 (20.9%)	100 (12.6%)
GFF MDI 14.4/9.6 μg	66	788	56 (84.8%)	717 (91.0%)	10 (15.2%)	71 (9.0%)
GFF MDI 115.2/38.4 μg	66	758	50 (75.8%)	647 (85.4%)	16 (24.2%)	111 (14.6%)


	Total N		QRS<=110 ms		QRS>110 ms	
Treatment Group	Subj. #	Obs. #	Subj. #	Obs. #	Subj. #	Obs. #
GP MDI 115.2 μg	66	782	53 (80.3%)	701 (89.6%)	13 (19.7%)	81 (10.4%)


5.3 CLINICAL PHARMACOLOGY ASSESSMENTS

The relationship between $\Delta\Delta$ QTcI and and formoterol fumarate concentrations is shown in Table 18 and visualized in Figure 6, with significant exposure-response relationship (P<0.0001).

Parameter	Estimate	P- value	Inter-individual Variability
$\Delta \Delta QTcI = Intercept + slope *Formoterol$			
Concentration			
Intercept (ms)	1.257	0.05	4.565
Slope (ms per ng/mL)	0.206	< 0.00	0.224
		01	
Residual Variability (ms)	6.883		


Table 18: Exposure- ΔΔQTcI Analysis for Formoterol





The goodness-of-fit plot in Figure 7 shows the observed median-quantile of Formoterol Fumarate concentrations and associated mean (90% CI) $\Delta\Delta$ QTcI together with the mean (90% CI) predicted $\Delta\Delta$ QTcI.

Figure 7: Observed Median-Quantile Formoterol Fumarate Concentration and Associated Mean (90% CI) ΔΔQTcI (colored dots) Together with the Mean (90% CI) Predicted ΔΔQTcI (black line with shaded red area)



The predicted $\Delta\Delta$ QTcIs at the geometric mean peak concentrations of Formoterol Fumarate for 115.2/38.4 µg and 14.4/9.6 µg are shown in Table 19 and visualized in Figure 8. A marginal QTc prolongation could be expected at the geometric mean formoterol plasma concentration after a supra-therapeutic dose of 38.4 µg FF.

Table 19: Predicted ΔΔQTcI Interval at Geometric Mean Peak Formoterol
Fumarate Concentration

Treatment	Cmax	Prediced ΔΔQTcI	90% CI
GFF 115.2/38.4 μg	39.31 pg/mL	9.38	(7.47; 11.28)
GFF 14.4/9.6 μg	8.06 pg/mL	2.92	(2.05; 3.78)




Figure 8: Mean (90% CI) Predicted ΔΔQTcI at Geometric Mean Cmax.

5.4 CLINICAL ASSESSMENTS

5.4.1 Safety assessments

None of the events identified to be of clinical importance per the ICH E 14 guidelines (i.e., syncope, seizure, significant ventricular arrhythmias or sudden cardiac death) occurred in this study.

5.4.2 ECG assessments

Overall ECG acquisition and interpretation in this study appears acceptable.

5.4.3 PR and QRS Interval

One subject withdrew for PR prolongation, but there did not seem to be any clinically significant systematic effect on PR or QRS.

6 APPENDIX

6.1 HIGHLIGHTS OF CLINICAL PHARMACOLOGY

	J	ar Fharmacology and Cardiac Salety
1.	Therapeutic dose (glycopyrrolate doses expressed; refer to Table 2 for glycopyrronium equivalent doses)	The maximum proposed clinical dosing regimen will be GP MDI 18 μ g BID, and GFF MDI 18/9.6 μ g, and FF MDI 9.6 μ g.
2.	Maximum tolerated dose (glycopyrrolate doses expressed; refer to Table 2 for glycopyrronium equivalent doses)	Not identified. GFF MDI 144 /38.4 μ g, GP MDI 144 μ g and FF MDI 19.2 μ g were the highest doses studied and were tolerated.
3.	Principal adverse events	Below is a summary of principal adverse events in Phase 1 studies:
		In Study PT010001, the most frequently reported TEAE among the 78 subjects who received GFF MDI 14.4/9.6 µg was hypokalemia, which was reported by 3 subjects (3.8%). In Study PT0010801, of 33 subjects enrolled and treated with at least 1 dose of study drug the most frequently reported TEAE was dry mouth, reported by 4.8%, 14.3%, 0, and 4.8% of subjects exposed to GP MDI 144 µg, 72 µg, 36 µg, and 18 µg, respectively, 9.5% of subjects exposed to Placebo MDI, and 9.1% of subjects exposed to Spiriva.
		In Study PT0050801, of the 34 subjects enrolled and treated with at least 1 dose of study drug, headache was the most frequently reported TEAE (5 events following FF MDI 2.4 μ g, 1 following FF MDI 9.6 μ g, 2 following Foradil, and 2 following Placebo MDI) followed by dyspnea (1 event following FF MDI 2.4 μ g, 1 following FF MDI 4.8 μ g, 1 following Foradil, and 2 following Placebo MDI).
		In Study PT005003, of the 50 subjects enrolled and treated with at least 1 dose of study drug the most frequently reported TEAEs were tremor and nasopharyngitis, each reported in 2 subjects (4.0%) overall; tremor was reported in 1 subject while receiving FF MDI 19.2 μ g and again while receiving Foradil 12 μ g, and in another subject while receiving Foradil 12 μ g; nasopharyngitis was reported in 2 subjects receiving Foradil 24 μ g.
		In Study PT0030901, of the 16 subjects enrolled and treated with at least 1 dose of study drug, the most frequently reported TEAEs were headache (reported for 33% of subjects following GFF MDI and \leq 13% following the other treatments) and dry mouth (13% to 27% across the 4 treatments).
		In Study PT003009, of the 69 subjects enrolled and treated with at least 1 dose of study drug, the incidence of TEAEs

Highlights of Clinical Pharmacology and Cardiac Safety

for each of the 4 active treatments, regardless of relationship to study drug never exceeded the incidence observed for placebo MDI and the incidence of treatment- related TEAEs for each of the 4 active treatments was slightly less than the incidence for placebo MDI.
In Study PT003010, of the 24 subject enrolled and treated with at least 1 dose of study drug, treatment-emergent AEs reported by Preferred Term that occurred in ≥ 2 subjects overall included dizziness, headache, and anemia (4 subjects [16.7%] each), injection site pain and dysmenorrhea (3 subjects [12.5%] each), and somnolence (2 subjects [8.3%]).
Below is a summary of principal adverse events based on the integrated analysis of Phase IIb chronic dosing studies (Studies PT001002, PT001003, PT0031002, PT003003, PT003004, and PT003005):
The incidence rate of AEs was highest among patients receiving GFF MDI 72/9.6 μ g. The lowest incidence of AE's within the GFF MDI treatments occurred in patients receiving GFF MDI 1.2/9.6 μ g (14.7%) followed by GFF MDI 18/9.6 μ g (23.4%).
The incidence rate of AEs in patients treated with GP MDI was highest in patients treated with GP MDI 36 μ g. There did not appear to be a dose ordering for GP MDI doses between 18 and 0.6 μ g and the incidence rate of AEs in this range of doses was lower than in patients receiving Spiriva or Atrovent.
The incidence of AEs in patients treated with FF MDI was comparable to and slightly lower than patients treated with Foradil Aerolizer.
The most frequently reported AE within all of the treatments was dry mouth, with the highest incidence occurring in patients treated with GFF MDI 72/9.6 μ g. The most frequently reported TEAEs (those reported in \geq 3% of subjects during any treatment) within the first 7 days of each treatment period were compared for subjects treated with GFF MDI, GP MDI, and FF MDI. The most frequently reported TEAE over 7 days across all treatments was dry mouth in 6.6%, 8.0%, and 5.3% of subjects treated with GFF MDI, GP MDI, and FF MDI overall, respectively, compared with 4.7%, 2.1%, 3.5%, and 2.5% in subjects treated with Spiriva, Atrovent, Foradil

	Aerolizer, and Placebo MDI, respectively. The second most frequently reported TEAE across all treatments was headache in 2.7%, 0.9%, and 0.4% of subjects during treatment with GFF MDI, GP MDI, and FF MDI, respectively; there was no apparent evidence of dose ordering across the individual doses. The third most frequently reported TEAE was tremor in 3.2% of subjects treated with GFF MDI and 3.6% of subjects treated with FF MDI; there was no apparent dose ordering across individual GFF MDI doses.
	Below is a summary of principal adverse events based on the integrated Phase III Pivotal 24-Week Studies (Studies PT003006 and PT003007):
	Across treatment groups, the most frequently reported TEAEs by Preferred Term were nasopharyngitis, upper respiratory tract infection, and cough; the incidences of these events in the GFF MDI 14.4/9.6 μ g, FF MDI 9.6 μ g, and GP MDI 14.4 μ g groups were generally similar to or lower than the incidences in the Placebo MDI and Spiriva 18 μ g groups.
	The most commonly reported TEAEs in the GFF MDI 14.4/9.6 μ g group that occurred at higher incidences (at least 1 percentage point higher) compared with the Placebo MDI group were cough (4.0% vs 2.7%, respectively) and dry mouth (1.3% vs 0.2%, respectively), although the differences in incidence were small (<2%). The incidences of the most common TEAEs in the GFF MDI 14.4/9.6 μ g group were generally similar to the incidences in the FF MDI 9.6 μ g and GP MDI 14.4 μ g individual component groups and the Spiriva 18 μ g group, with differences between groups generally being 1% to 2%.
	Below is a summary of principal adverse events based on the integrated Phase III Pivotal and Long-Term Studies (Studies PT003006, PT003007 and PT003008) during 52 weeks of treatment:
	The most commonly reported TEAEs (in \geq 3.0% of subjects) in the GFF MDI 14.4/9.6 µg group were nasopharyngitis (6.8%), cough (4.2%), upper respiratory tract infection (3.8%), urinary tract infection (UTI; 3.5%), COPD (includes COPD exacerbations and COPD worsening; 3.2%), and sinusitis (3.2%). The incidences of the most common TEAEs in the GFF MDI 14.4/9.6 µg group were generally similar in the FF MDI 9.6 µg and GP

			idual component groups and the Spiriva
		nasopharyngitis in	the exception of a lower incidence of the GP MDI 14.4 µg group (GFF MDI
			FF MDI 9.6 μg: 6.2%, GP MDI 14.4 μg:
			g: 6.2%) and a higher incidence of eflux disease (GERD) in the Spiriva 18
			DI 14.4/9.6 μg: 0.9%, FF MDI 9.6 μg:
			4 µg: 1.0%, Spiriva 18 µg: 3.1%).
4.	Maximum dose tested	Single Dose	GFF MDI 144 /38.4 µg
	(glycopyrrolate doses expressed;	-	GP MDI 144 µg
	refer to Table 2 for		FF MDI 19.2 µg
	glycopyrronium equivalent doses)	Multiple Dose	GFF MDI 72/9.6 µg BID x7 days
		_	(glycopyrrolate doses expressed; refer
			to Table 2 for glycopyrronium
			equivalent doses):
			GP MDI 36 µg BID x7 days (i.e., 36
			μg glycopyrrolate, equivalent to 28.8
			μg glycopyrronium) FF MDI 9.6 μg BID x24 weeks
5.	Exposures Achieved at Maximum	Single Dose	Mean (±SD) were as follows:
	Tested Dose	Single Dose	GFF MDI 144/38.4 µg:
	(Glycopyrrolate doses expressed;		 Glycopyrronium=105 (±156)
	refer to Table 2 for		pg/mL for C _{max} and was 179
	glycopyrronium equivalent doses)		(±102) pg.h/mL for AUC ₀₋₁₂
			 FF = 39.4 (±21.8) pg/mL for
			C _{max} and was 148 (±59.0)
			pg.h/mL for AUC ₀₋₁₂
			 GP MDI 144 μg: 160 (±118)
			pg/mL for C _{max} and AUC ₀₋₁₂ was
			398 (±318) pg.h/mL.
			 FF MDI 19.2 μg: 21.2
			(± 10.1) pg/mL for C _{max} and
			AUC ₀₋₁₂ was 107 (±40.6) pg.h/mL
		Multiple Dose	Mean $(\pm SD)$ were as follows:
			GFF MDI 72/9.6 µg BID x7 days
			(glycopyrrolate doses expressed; refer
			to Table 2 for glycopyrronium equivalent doses):
			 Glycopyrronium= 179 (±161)
			pg/mL for C _{max} and was 605
			(± 345) pg.h/mL for AUC ₀₋₁₂
			\circ FF = 18.2 (±10.2) pg/mL for
			C_{max} and was 115 (±58.3)
			pg.h/mL for AUC ₀₋₁₂
			 GP MDI 36 µg BID x7 days:
			98.2 (67.0) pg/mL for C _{max} and was
			357 (205) pg.h/mL for AUC ₀₋₁₂

·		1	1
			 FF MDI 9.6 μg BID x24 weeks: 12.3 (6.12) pg/mL for C_{max} and was 75.7 (44.4) pg.h/mL for AUC₀₋₁₂
6.	Range of linear PK (glycopyrrolate doses expressed; refer to Table 2 for glycopyrronium equivalent doses):	generally in propor departure from dos µg glycopyrrolate, glycopyrronium) a Systemic exposure	sure of glycopyrronium increased tion to the dose. There was a slight e linearity at the highest dose level (144 equivalent to 115.2 µg of ccording to the population PK model. to formoterol from FF MDI ar linear relationship across the single
7.	Accumulation at steady state (glycopyrronium doses expressed; refer to Table 2 for glycopyrrolate equivalent doses):	dosage range (2.4 μ PT003006: • Glycopyrro GFF MDI [90% CIs: [90% CIs: [90% CIs: • Glycopyrro MDI 14.4 1.65, 2.42] based on C • Formoterol MDI 14.4/ 1.69] based on C _{max} . • Formoterol 9.6 μg chro	ag to 19.2 μg formoterol fumarate). onium accumulation ratios following 14.4/9.6 μg chronic dosing were 2.30 2.04, 2.59] based on AUC ₀₋₁₂ and 1.40 1.22, 1.59] based on C _{max} . onium accumulation ratios following GP μg chronic dosing were 2.00 [90% CIs: based on AUC ₀₋₁₂ and 1.26 [1.06, 1.50]
8.	Metabolites	formoterol is by di demethylation follo metabolites. Secon deformylation and	onium; the primary metabolism of rect glucuronidation and by O- owed by conjugation to inactive dary metabolic pathways include sulfate conjugation. CYP2D6 and identified as being primarily responsible on.
9.	Absorption (glycopyrronium doses expressed; refer to Table 2 for glycopyrrolate equivalent doses):	Absolute/Relative Bioavailability Tmax	 N/A Glycopyrronium: Following inhaled administration of GFF MDI at the recommended dose in subjects with COPD, peak concentrations occurred at 5 minutes. Across the range of doses tested: Median t_{max} ranged from 0.06 to 0.100 h (minimum: 0.03 h; maximum: 8.00 h) for single dose

			 GFF MDI 14.4/9.6 μg to GFF MDI 115.2/38.4 μg Median t_{max} ranged from 0.083 to 0.100 h (minimum: 0.00 h; maximum: 7.93 h) for multiple dose GFF MDI 14.4/9.6 μg to GFF MDI 72/9.6 μg BID Median t_{max} ranged from 0.07 to 0.333 h (minimum: 0.033 h; maximum: 5.00 h) for single dose GP MDI 14.4 μg to GP MDI 115.2 μg Median t_{max} ranged from 0.083 to 0.100 h (minimum: 0.00 h; maximum: 12.00 h) for multiple dose GP MDI 14.4 μg to GP MDI 36 μg Formoterol: Following inhaled administration of GFF MDI at the recommended dose in subjects with COPD, peak concentrations occurred within 20 to 60 minutes. Across the range of doses tested: Median t_{max} ranged from 0.10 to 0.583 h (minimum: 0.03 h; maximum: 8.00 h) for single dose GFF MDI 14.4/9.6 μg to GFF MDI 115.2/38.4 μg Median t_{max} ranged from 0.367 to 1.01 h (minimum: 0.03 h; maximum: 9.97 h) for multiple dose GFF MDI 14.4/9.6 μg to GFF MDI 72/9.6 μg BID Median t_{max} ranged from 0.38 to 1.42 h (minimum: 0.033; maximum: 12.0) for single dose FF MDI 2.4 μg to FF MDI 19.2 μg Median t_{max} ranged from 0.917 to 0.983 h (minimum: 0.033 h; maximum: 9.92 h) for multiple dose FF MDI 7.2 μg to FF MDI 9.6 μg
10.	Distribution	Vc/F	 Typical Vc/F and V2/F of glycopyrronium were 951 L and 2019 L, respectively for

			altraanteranium
			glycopyrronium Typical Vc/F and V2/F of
			formoterol were 948 L and 434 L,
			respectively
		% bound	N/A for glycopyrronium; 46% and
			58% for formoterol based on
			Symbicort MDI PI.
11.	Elimination	Route	In both urine and bile, > 80% of the
			radioactivity corresponded to
			unchanged drug and 5 to 15% as the
			alkaline hydrolysate of
			glycopyrronium (Kaltiala, 1974)
		Terminal t ¹ / ₂	Based on the population PK model, the
			terminal elimination half-lives of
			glycopyrronium and formoterol were
			both 11.8 hours.
		CL/F or CL	 The typical CL/F of
			glycopyrronium was 217 L/h (i.e.,
			3.6 L/min).
			 The typical CL/F of formoterol was
			102 L/h (i.e., 1.7 L/min).
12.	Intrinsic Factors	Age	The final population PK model of
			glycopyrronium included an effect of
			age on Ka power function of -2.44
			[(Age/62) ^{-2.44}], and CL/F with a power
			function of -1.33 [(Age/62) ^{-1.33}]. Based
			on this model, the Ka of
			glycopyrronium in typical 79-year old
			subject would be ~45% lower than in a
			typical 62 year old subject. The CL/F
			of glycopyrronium in a typical 40 and
			79-year old subject would be expected
			to be approximately 79% higher and
			28% lower relative to a typical 62-year
			old subject, respectively.
		Sex	Sex was not an identified as significant
			covariates explaining the variability of
			PK parameters of glycopyrronium and
			formoterol. Of note, the mean effect of
			sex on glycopyrronium CL/F was a
1			16% increase in clearance for men
1			relative to women and was not
1			statistically significant (p-value =
1			0.1768). The mean effect of sex on
1			formoterol CL/F was an 11% increase
1			in clearance for men relative to women
			and was not statistically significant (p-
			value = 0.1276).

<u> </u>			mention Develop the first
			excretion. Based on the final population PK model,
			glycopyrronium CL/F was found to
			be dependent on baseline creatinine
			clearance. The power function of
			baseline creatinine clearance
			(CRCLBSLC) on CL/F was 0.250 [(CRCLBSLC/94.2) ^{0.250}]. The
			typical CL/F of glycopyrronium in
			patients with moderate renal
			impairment (45 mL/min creatinine
			clearance) is expected to be
			approximately 17% lower than
			subjects with normal renal function
			(creatinine clearance of 94.2
			mL/min).
			Specific pharmacokinetic
			information in patients with hepatic
			impairment with formoterol
			fumarate is not available, however
			formoterol is primarily eliminated
			via hepatic metabolism, thus an
			increased exposure can be expected
			in subjects with severe liver
			impairment. Based on the final
			population PK model, formoterol
			CL/F was found to be dependent
			on baseline creatinine clearance (CRCLBSLC).
			The power function of baseline
			creatinine clearance on CL/F was
			0.502 [(CRCLBSLC/94.0) ^{0.502}].
			Based on this model, the CL/F of
			formoterol in patients with
			moderate renal impairment
			(45 mL/min creatinine clearance) is
			expected to be approximately 31%
			slower than subjects with normal
			renal function (creatinine clearance
			of 94 mL/min).
13.	Extrinsic Factors	Drug interactions	No interaction was detected following
			co-administration of glycopyrronium
			and formoterol fumarate based on
			studies conducted in healthy and
			COPD subjects. According to the
			population model, when given as GFF
			MDI the mean apparent oral plasma
			clearance of glycopyrronium was

		Food Effects	statistically significant compared to when given as GP MDI (monoproduct) but only 18% higher, according to the population model. Thus, co- administration with formoterol fumarate as the fixed combination GFF MDI did not result in a clinically relevant effect on the PK parameters of glycopyrronium. Also, based on the PK model, the Vc/F of glycopyrronium and formoterol were dependent on the use of ICS. The typical Vc/F of glycopyrronium in subjects taking ICS at baseline was 36% (RSE of 19.2%) larger than subjects who did not take ICS. The typical Vc/F of formoterol in subjects taking ICS at baseline was 32% (RSE of 14.5%) larger than subjects who did not take ICS. N/A
14.	Expected High Clinical Exposure Scenario	glycopyrronium Al moderate renal imp 128 pg*h/mL (1.9- of 66.4 pg*h/mL b CrCL=94.2 mL/mi with severe renal in predicted glycopyr fold higher than the Following a dose of formoterol AUC ₀₋₁₂ of 0.64 L and moder mL/min) is 168 pg reference AUC ₀₋₁₂ , post-ventolin FEV Figure 4). In a sub with severe renal in predicted formoter higher than the refer	
15.	Preclinical Cardiac Safety		<i>itro</i> studies conducted.
		studies support the significant toxicity	s of the rat and dog inhalation toxicology presumption that GFF MDI yields no other than cardiac alterations (i.e. e) previously reported for formoterol

		fumarate-containing approved drugs such as Symbicort [®] MDI. The cardiac findings observed in the 14-day studies were not present in the 3-month dog study with either GFF MDI or FF MDI, suggesting that the cardiac findings were temporary adaptations which subsided upon longer term exposure. The GP MDI studies that dosed up to 6 months in dogs and rats had no significant observations, and the FF MDI studies up to 3 months in dogs had similar profiles to the GFF MDI studies and other formoterol fumarate- containing approved drugs. Additionally, no new, unusual, or interactive adverse effects were observed compared to the previous animal inhalation studies. See Section 2.6.6 Toxicology Written Summary for further details.
16	Clinical Cardias Safety	
10.	Clinical Cardiac Safety	Below is a summary of principal adverse events in Phase 1 studies:
	(glycopyrronium doses expressed;	studies:
	refer to Table 2 for glycopyrrolate equivalent doses):	In Study PT010001, the most frequently reported TEAE among the 78 subjects who received GFF MDI 14.4/9.6 µg was hypokalemia, which was reported by 3 subjects (3.8%). In Study PT0010801, of 33 subjects enrolled and treated with at least 1 dose of study drug the most frequently reported TEAE was dry mouth, reported by 4.8%, 14.3%, 0, and 4.8% of subjects exposed to GP MDI 144 µg, 72 µg, 36 µg, and 18 µg, respectively, 9.5% of subjects exposed to Placebo MDI, and 9.1% of subjects exposed to Spiriva. In Study PT0050801, of the 34 subjects enrolled and treated with at least 1 dose of study drug, headache was the most frequently reported TEAE (5 events following FF MDI 2.4
		 μg, 1 following FF MDI 9.6 μg, 2 following Foradil, and 2 following Placebo MDI) followed by dyspnea (1 event following FF MDI 2.4 μg, 1 following FF MDI 4.8 μg, 1 following Foradil, and 2 following Placebo MDI). In Study PT005003, of the 50 subjects enrolled and treated with at least 1 dose of study drug the most frequently reported TEAEs were tremor and nasopharyngitis, each
		reported in 2 subjects (4.0%) overall; tremor was reported in 1 subject while receiving FF MDI 19.2 μ g and again while receiving Foradil 12 μ g, and in another subject while receiving Foradil 12 μ g; nasopharyngitis was reported in 2 subjects receiving Foradil 24 μ g. In Study PT0030901, of the 16 subjects enrolled and treated with at least 1 dose of study drug, the most frequently reported TEAEs were headache (reported for 33% of subjects following GFF MDI and ≤13% following the other
		reported TEAEs were headache (reported fo

treatments).
reaments).
In Study PT003009, of the 69 subjects enrolled and treated with at least 1 dose of study drug, the incidence of TEAEs for each of the 4 active treatments, regardless of relationship to study drug never exceeded the incidence observed for placebo MDI and the incidence of treatment- related TEAEs for each of the 4 active treatments was slightly less than the incidence for placebo MDI. The largest mean (95% upper confidence bound) differences from placebo in baseline-corrected QTcI for GFF MDI 14.4/9.6 μ g and GFF MDI 115.2/38.4 μ g (i.e., 115.2 μ g glycopyrronium, equivalent to 144 μ g glycopyrrolate, and 38.4 μ g formoterol), were 3.1 (4.7) ms and 7.6 (9.2) ms, respectively, and excluded the clinically relevant threshold of 10 ms. Therefore, single dose administration of GFF MDI and supra-therapeutic doses of glycopyrrolate/formoterol fumarate do not prolong the QT interval. Refer to Table 15 to Table 16 for the different drug exposure levels.
In Study PT003010, of the 24 subject enrolled and treated with at least 1 dose of study drug, treatment-emergent AEs reported by Preferred Term that occurred in ≥ 2 subjects overall included dizziness, headache, and anemia (4 subjects [16.7%] each), injection site pain and dysmenorrhea (3 subjects [12.5%] each), and somnolence (2 subjects [8.3%]).
Below is a summary of principal adverse events based on the integrated analysis of Phase II chronic dosing studies:
Cardiovascular safety has been evaluated throughout the Phase I/II program. More than 36,000 ECGs have been evaluated with no unexpected findings considering the class of drugs and population under study. Furthermore, a specific cardiovascular safety study, Study PT003003, assessed cardiovascular effects with Holter monitoring.
In the Phase III program, one of the pivotal 24-week studies, Study PT003007, included a 24-hour Holter monitoring sub-study, as well as a comprehensive evaluation of ECGs throughout the Phase III program. No clinically relevant findings were observed at the tested doses of GFF MDI 18/9.6 µg BID (i.e., 18 µg glycopyrrolate, equivalent to 14.4 µg glycopyrronium, and 9.6 µg formoterol), GP MDI 18 µg BID (i.e., 18 µg glycopyrrolate, equivalent to 14.4 µg glycopyrronium) and

FF MDI 9.6 µg BID. The cardiac safety results are described in detail in Section 2.7.3 Summary of Clinical Efficacy.
Clinical cardiac safety for all studies are presented in detail in Integrated Summary of Safety Section 4.1.2 (Overall) and 4.1.2.4 (Summary).

Source: Summary of Clinical Pharmacology Studies, Table 11, page 68-80

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

HUIFANG CHEN 09/21/2015

QIANYU DANG 09/21/2015

JINGYU YU 09/21/2015

JIANG LIU 09/21/2015

MICHAEL Y LI 09/22/2015

NORMAN L STOCKBRIDGE 09/22/2015

RPM FILING REVIEW

(Including Memo of Filing Meeting) To be completed for all new NDAs, BLAs, and Efficacy Supplements [except SE8 (labeling change with clinical data) and SE9 (manufacturing change with clinical data]

	Applica	tion Informat	tion
NDA # 208294	NDA Supplement #	#: S-	Efficacy Supplement Category:
BLA#	BLA Supplement #	ŧ: S-	New Indication (SE1)
			New Dosing Regimen (SE2)
			New Route Of Administration (SE3)
			Comparative Efficacy Claim (SE4)
			New Patient Population (SE5)
			Rx To OTC Switch (SE6)
			Accelerated Approval Confirmatory Study
			(SE7)
			Labeling Change With Clinical Data (SE8)
			Manufacturing Change With Clinical Data (SE9)
			Animal Rule Confirmatory Study (SE10)
Proprietary Name:			
Established/Proper Name:	Glycopyrrolate and l	Formoterol fum	urate
Dosage Form: Inhalation a			
Strengths: 9mcg/4.8mcg			
Applicant: Pearl Therapeut	tics Inc.		
Agent for Applicant (if app			
Date of Application: June			
Date of Receipt: June 25, 2	2015		
Date clock started after UN	:		
PDUFA Goal Date: April 2	5,2016	Action Goal D	ate (if different):
Filing Date: August 24, 20	15	Date of Filing	Meeting: August 3, 2015
Chemical Classification (or	iginal NDAs only) :		
Type 1- New Molecular E	ntity (NME); NME and	d New Combinati	on
	dient; New Active Ing	redient and New l	Dosage Form; New Active Ingredient and New
Combination			
Type 3- New Dosage Form	-	and New Combina	ation
Type 4- New Combination			
Type 5- New Formulation			
Type 7- Drug Already Ma		ved NDA	
Type 8- Partial Rx to OTC			
Proposed indication: COPE	,		
Type of Original NDA:			505(b)(1)
AND (if applicable)		∑ 505(b)(2)
Type of NDA Supplement:			505(b)(1)
			505(b)(2)
If 505(b)(2): Draft the "505(b) http://inside.fda.gov:9003/CDER/0f)			
mp.//msuc.juu.gov.7005/CDEROJJ	iccoji tonist ngs/immediale	<u>omeo e emozrazz</u> .	

Type of BLA		351(a)			
If 251(h) we dide the OND Theorem and a Ris	351(k)				
<i>If 351(k), notify the OND Therapeutic Bio</i> Review Classification:	logics and biosimilars leam	Standard	1		
Review Classification.		Priority	1		
The application will be a priority review if					
		Pediatrie	WD		
	 A complete response to a pediatric Written Request (WR) was included (a partial response to a WR that is sufficient to change 				
the labeling should also be a prior		Disease Priority			
	• The product is a Qualified Infectious Disease Product (QIDP)				
	 A Tropical Disease Priority Review Voucher was submitted 				
A Pediatric Rare Disease Priority		Review Vou	Rare Disease Priority		
Resubmission after withdrawal?	Resubmission				
Part 3 Combination Product?	Convenience kit/Co-packag				
	Pre-filled drug delivery dev		ringe, patch, etc.)		
If yes, contact the Office of	Pre-filled biologic delivery				
Combination Products (OCP) and copy	Device coated/impregnated				
them on all Inter-Center consults	Device coated/impregnated				
Separate products requiring cross-labeling					
	Drug/Biologic		,		
	Possible combination based	on cross-label	ing of separate		
	products		0 1		
	Other (drug/device/biologic	al product)			
		• /			
Fast Track Designation	PMC response				
Breakthrough Therapy Designation					
(set the submission property in DARRTS and	FDAAA [505(0)]				
notify the CDER Breakthrough Therapy	PREA deferred peo	diatric studies	(FDCA Section		
Program Manager)	505B)				
Rolling Review	Accelerated appro	val confirmato	ry studies (21 CFR		
Orphan Designation	314.510/21 CFR 601.4				
Dr. to OTC switch Full	Animal rule postm	arketing studie	es to verify clinical		
Rx-to-OTC switch, Full	benefit and safety (21				
Rx-to-OTC switch, Partial			,		
Other:					
Collaborative Review Division (if OTC					
List referenced IND Number(s):	^{(b) (4)} 107739				
Goal Dates/Product Names/Classi	fication Properties YES	NO NA	Comment		
PDUFA/BsUFA and Action Goal dates					
system?					
If no, ask the document room staff to corre	ect them immediately.				
These are the dates used for calculating in					
Are the established/proper and applican	t names correct in				
tracking system?					
If no, ask the document room staff to make		1			
ask the document room staff to add the est					

to the supporting IND(s) if not already entered into track	ing				
system. Is the review priority (S or P) and all appropriate classifications/properties entered into tracking system chemical classification, combination product classific orphan drug)? Check the New Application and New Sup Notification Checklists for a list of all classifications/prop at: <u>http://inside.fda.gov:9003/CDER/OfficeofBusinessProcessSupport/ucm</u> m	cation, plement perties				
If no, ask the document room staff to make the appropria entries.	ıte				
Application Integrity Policy		YES	NO	NA	Comment
Is the application affected by the Application Integrit (AIP)? Check the AIP list at: <u>http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPothtm</u>			\boxtimes		
If yes, explain in comment column.					
If affected by AIP, has OC been notified of the submission? If yes, date notified:					
User Fees		YES	NO	NA	Comment
Is Form 3397 (User Fee Cover Sheet)/Form 3792 (Bi User Fee Cover Sheet) included with authorized sign		\boxtimes			
<u>User Fee Status</u> If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter and contact user fee staff.	UserFeel Paid Exen	<u>4R@fda.</u> npt (orpl	<u>hhs.gov</u>) han, go): vernme	heck daily email from ent) ss, public health)
If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter	UserFeel Paid Exen	<u>4R@fda.</u> npt (orpl zed (e.g. required	hhs.gov han, go , small): vernme busines	ent)
If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter and contact user fee staff. If the firm is in arrears for other fees (regardless of whether a user fee has been paid for this application), the application is unacceptable for filing (5-day grace period does not apply). Review stops. Send UN letter	UserFee Paid Exen Waiv Not 1 Payment	AR@fda npt (orpl ved (e.g. required t of othe	<u>hhs.gov</u> han, go , small r user f): vernme busines	ent)
If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter and contact user fee staff. If the firm is in arrears for other fees (regardless of whether a user fee has been paid for this application), the application is unacceptable for filing (5-day grace	UserFeed Paid Exen Waiv Not i Payment Not i In art Has the	AR@fda npt (orpl ved (e.g. required t of othe in arrear rears user fee If no, or	han, gov , small r user f s bundlin): vernme busines èees: ng polic	ent)
If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter and contact user fee staff. If the firm is in arrears for other fees (regardless of whether a user fee has been paid for this application), the application is unacceptable for filing (5-day grace period does not apply). Review stops. Send UN letter and contact the user fee staff. User Fee Bundling Policy Refer to the guidance for industry, Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulator	UserFee Paid Exen Waiv Not i Payment Not i In an Has the applied? Fee Staff Yes	AR@fda npt (orpl ved (e.g. required t of othe in arrear rears user fee If no, or	han, gov , small r user f s bundlin): vernme busines èees: ng polic	ent) ss, public health) cy been appropriately

<i>cover letter, and annotated</i> questions below:	labeling). If yes, answe	er the bulleted					
	r a duplicate of a listed of	drug and		\boxtimes			
	under section 505(j) as						
Is the application for	a duplicate of a listed of	lrug whose		\boxtimes			
	at the extent to which th						
	rbed or otherwise made						
	ess than that of the refer						
drug (RLD)? [see 21	CFR 314.54(b)(1)].						
	a duplicate of a listed of	trug whose		\boxtimes			
	at the rate at which the p						
	redient(s) is absorbed or	-					
	of action is unintentiona						
	g [see 21 CFR 314.54(t						
that of the listed drug	5 [300 21 01 10 01 4.34(1	,,(_)].					
If you answered yes to any	of the above bulleted que	estions, the					
application may be refused							
314.101(d)(9). Contact the	505(b)(2) review staff in	the Immediate					
Office of New Drugs for a	dvice.						
• Is there unexpired ex	clusivity on another list	ted drug	\boxtimes				
product containing t	he same active moiety (e.g., 5-year,					
3-year, orphan, or pe	ediatric exclusivity)?						
Check the Electronic Oran							
http://www.accessdata.fda.gov/sc	ripts/cder/ob/default.cfm						
If yes, please list below:			Ļ				
Application No.	Drug Name	Exclusivity Co	ode			Expiration	
		Exclusivity Co	ode		lusivity 28/2017		
Application No.	Drug Name		ode				
Application No. NDA 022571	Drug Name Cuvposa	ODE		07/2	28/2017	1	
Application No. NDA 022571 If there is unexpired, 5-yea	Drug Name Cuvposa r exclusivity remaining on	ODE another listed a	lrug prod	07/2	28/2017	he same activ	
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the	ODE another listed a period of exclu	lrug prod sivity exp	07/2	28/2017 aining t	he same activ applicant pro	vides
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application car paragraph IV patent certifi	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio	ODE another listed a period of exclu- m can be submit	lrug prod sivity exp ted four y	07/2 luct cont ires (uni vears aft	28/2017 Caining to less the o er the do	he same activ applicant pro- ate of approve	vides 11.)
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will es	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram	ODE another listed a period of exclu m can be submit es in this provisi	drug prod sivity exp ted four y ion by 6 n	07/2 uct cont ires (unu rears aft nonths.	aining ti aiss the d er the dd 21 CFR	he same activ applicant pro- ate of approva 314.108(b)(2)	vides 11.)
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will es Unexpired, 3-year exclusiv	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram	ODE another listed a period of exclu m can be submit es in this provisi	drug prod sivity exp ted four y ion by 6 n mission o	07/2 Juct cont ires (uni gears aft nonths of a 505(28/2017 caining t less the d er the da 21 CFR b)(2) ap	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva	ODE another listed a period of exclu- m can be submit es in this provis- l but not the sub	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining ti aiss the d er the dd 21 CFR	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will es Unexpired, 3-year exclusivity Exclusivity Does another product (sa	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have	ODE another listed a period of exclu m can be submit es in this provisu l but not the sub corphan	drug prod sivity exp ted four y ion by 6 n mission o	07/2 Juct cont ires (uni gears aft nonths of a 505(28/2017 caining t less the d er the da 21 CFR b)(2) ap	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the O	ODE another listed a period of exclu m can be submit es in this provisu l but not the sub corphan	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	28/2017 caining t less the d er the da 21 CFR b)(2) ap	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approval	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the On als list at:	ODE another listed of period of exclu- m can be submit es in this provis- l but not the sub c orphan rphan Drug	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	28/2017 caining t less the d er the da 21 CFR b)(2) ap	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifit Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sc	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the On als list at: ripts/opdlisting/oopd/index.cfm	ODE another listed a period of exclu- m can be submit es in this provisi l but not the sub c orphan rphan Drug	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sc If another product has	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Of its list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is t	ODE another listed a period of exclu- m can be submit- es in this provise l but not the sub c orphan rphan Drug the product	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	28/2017 caining to less the do er the do 21 CFR b)(2) ap	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will es Unexpired, 3-year exclusiv Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sec If another product has considered to be the same	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Of als list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the	ODE another listed a period of exclu- in can be submit es in this provisi l but not the sub c orphan rphan Drug the product the orphan	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sc If another product has	Drug Name Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Of als list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the	ODE another listed a period of exclu- in can be submit es in this provisi l but not the sub c orphan rphan Drug the product the orphan	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifit Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sc If another product has considered to be the same	Drug Name Cuvposa Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Of als list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the less [see 21 CFR 316.3(ODE another listed a period of exclu- m can be submit es in this provisi l but not the sub c orphan rphan Drug the product the orphan (b)(13)]?	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will es Unexpired, 3-year exclusiv Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sec If another product has considered to be the same	Drug Name Cuvposa Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the On the list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the esss [see 21 CFR 316.3(r, Division of Regulatory 1	ODE another listed a period of exclu- m can be submit es in this provisi l but not the sub c orphan rphan Drug the product the orphan (b)(13)]?	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifit Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sc If another product has considered to be the sam drug definition of samen If yes, consult the Director	Drug Name Cuvposa Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Or is list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the tess [see 21 CFR 316.3(r, Division of Regulatory 1	ODE another listed a period of exclu- m can be submit es in this provise l but not the sub c orphan rphan Drug the product the orphan (b)(13)]? Policy II,	drug prod sivity exp ted four y ion by 6 n mission o	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sc If another product has considered to be the sam drug definition of samen If yes, consult the Director Office of Regulatory Policy	Drug Name Cuvposa r exclusivity remaining on anot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Or als list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the active so of Regulatory is y pplements only: Has the	ODE another listed a period of exclu- in can be submit es in this provisi l but not the sub c orphan rphan Drug the product the orphan (b)(13)]? Policy II, the applicant	drug prod sivity exp ted four y ion by 6 n mission o YES	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/se If another product has considered to be the same drug definition of samen If yes, consult the Director Office of Regulatory Polic NDAs/NDA efficacy su	Drug Name Cuvposa r exclusivity remaining on anot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Or als list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the active so of Regulatory is y pplements only: Has the	ODE another listed a period of exclu- in can be submit es in this provisi l but not the sub c orphan rphan Drug the product the orphan (b)(13)]? Policy II, the applicant	drug prod sivity exp ted four y ion by 6 n mission o YES	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifi Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/se If another product has considered to be the same drug definition of samen If yes, consult the Director Office of Regulatory Polic NDAs/NDA efficacy su	Drug Name Cuvposa Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Or als list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the ess [see 21 CFR 316.3(r, Division of Regulatory 12 y pplements only: Has the ar Waxman-Hatch exclusion	ODE another listed a period of exclu- in can be submit es in this provisi l but not the sub c orphan rphan Drug the product the orphan (b)(13)]? Policy II, the applicant	drug prod sivity exp ted four y ion by 6 n mission o YES	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).
Application No. NDA 022571 If there is unexpired, 5-yea a 505(b)(2) application can paragraph IV patent certifit Pediatric exclusivity will ex Unexpired, 3-year exclusivity Exclusivity Does another product (sa exclusivity for the same Designations and Approva http://www.accessdata.fda.gov/sc If another product has considered to be the sam drug definition of samen If yes, consult the Director Office of Regulatory Polic NDAs/NDA efficacy su requested 5-year or 3-year	Drug Name Cuvposa Cuvposa r exclusivity remaining on mot be submitted until the ication; then an applicatio xtend both of the timefram ity may block the approva ame active moiety) have indication? Check the Or als list at: ripts/opdlisting/oopd/index.cfm orphan exclusivity, is the product according to the ess [see 21 CFR 316.3(r, Division of Regulatory 12 y pplements only: Has the ar Waxman-Hatch exclusion	ODE another listed a period of exclu- in can be submit es in this provisi l but not the sub c orphan rphan Drug the product the orphan (b)(13)]? Policy II, the applicant	drug prod sivity exp ted four y ion by 6 n mission o YES	07/2 luct cont ires (uni- vears aft nonths of a 505(NO	aining to less the de er the do 21 CFR b)(2) ap NA	he same activ applicant prov ate of approvo 314.108(b)(2, plication.	vides 11.)).

therefore, requesting exclusivity is not required.		
NDAs only : Is the proposed product a single enantiomer of a racemic drug previously approved for a different therapeutic use?	\boxtimes	
If yes, did the applicant: (a) elect to have the single enantiomer (contained as an active ingredient) not be considered the same active ingredient as that contained in an already approved racemic drug, and/or (b): request exclusivity pursuant to section 505(u) of the Act (per FDAAA Section 1113)? If yes, contact the Orange Book Staff (CDER-Orange Book		
Staff).		
BLAs only: Has the applicant requested 12-year exclusivity under section 351(k)(7) of the PHS Act? If yes, notify Marlene Schultz-DePalo, CDER Purple Book Manager		
Note: Exclusivity requests may be made for an original BLA submitted under Section 351(a) of the PHS Act (i.e., a biological reference product). A request may be located in Module 1.3.5.3 and/or other sections of the BLA and may be included in a supplement (or other correspondence) if exclusivity has not been previously requested in the original 351(a) BLA. An applicant can receive exclusivity without requesting it; therefore, requesting exclusivity is not required.		

Format and Content						
Do not check mixed submission if the only electronic component is the content of labeling (COL).	 All paper (except for COL) All electronic Mixed (paper/electronic) 					
	CTD Non-CTD Mixed (CTD/non-CTD)					
If mixed (paper/electronic) submission, which parts of the application are submitted in electronic format?						
Overall Format/Content	YES	NO	NA	Comment		
If electronic submission, does it follow the eCTD guidance? ¹ If not, explain (e.g., waiver granted).	\boxtimes					
Index: Does the submission contain an accurate comprehensive index?						
Is the submission complete as required under 21 CFR 314.50 (NDAs/NDA efficacy supplements) or under 21 CFR 601.2 (BLAs/BLA efficacy supplements) including:	\boxtimes					

¹

http://www_fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072349.pdf

 legible English (or translated into English) pagination navigable hyperlinks (electronic submissions only) If no, explain. BLAs only: Companion application received if a shared or divided manufacturing arrangement? If yes, BLA # 				
Forms and Certifications	1	I	I	
<i>Electronic</i> forms and certifications with electronic signatures (scann e.g., /s/) are acceptable. Otherwise, paper forms and certifications w. <i>Forms</i> include: user fee cover sheet (3397/3792), application form (2 disclosure (3454/3455), and clinical trials (3674); <i>Certifications</i> inclu- certification(s), field copy certification, and pediatric certification.	ith hand- 356h), pa	written s tent info	signatur rmation certifica	es must be included. (3542a), financial
Application Form	YES	NO	NA	Comment
Is form FDA 356h included with authorized signature per 21 CFR 314.50(a)? If foreign applicant, a U.S. agent must sign the form [see 21 CFR 314.50(a)(5)].	\boxtimes			
Are all establishments and their registration numbers listed	\boxtimes			
on the form/attached to the form?				
Patent Information	YES	NO	NA	Comment
	ILS	nu	INA	Comment
(NDAs/NDA efficacy supplements only) Is patent information submitted on form FDA 3542a per 21	\square			
CFR 314.53(c)?				
Financial Disclosure	YES	NO	NA	Comment
Are financial disclosure forms FDA 3454 and/or 3455 included with authorized signature per 21 CFR 54.4(a)(1) and (3)? Forms must be signed by the APPLICANT, not an Agent [see 21 CFR 54.2(g)].				
<i>Note:</i> Financial disclosure is required for bioequivalence studies that are the basis for approval.				
Clinical Trials Database	YES	NO	NA	Comment
Is form FDA 3674 included with authorized signature?				Language was added to acknowledgement

If no, ensure that language requesting submission of the form is				
included in the acknowledgement letter sent to the applicant	TITIC	NO		<u> </u>
Debarment Certification	YES	NO	NA	Comment
Is a correctly worded Debarment Certification included with authorized signature?				
Certification is not required for supplements if submitted in the original application; If foreign applicant, <u>both</u> the applicant and the U.S. Agent must sign the certification [per Guidance for				
Industry: Submitting Debarment Certifications].				
Note: Debarment Certification should use wording in FD&C Act Section $306(k)(1)$ i.e., "[Name of applicant] hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application." Applicant may not use wording such as, "To the best of my knowledge"				
Field Copy Certification	YES	NO	NA	Comment
(NDAs/NDA efficacy supplements only)				
For paper submissions only: Is a Field Copy Certification (that it is a true copy of the CMC technical section) included?			\boxtimes	
Field Copy Certification is not needed if there is no CMC				
technical section or if this is an electronic submission (the Field				
Office has access to the EDR)				
If maroon field copy jackets from foreign applicants are received, return them to CDR for delivery to the appropriate field office.				
Controlled Substance/Product with Abuse Potential	YES	NO	NA	Comment
For NMEs:			\boxtimes	
Is an Abuse Liability Assessment, including a proposal for scheduling, submitted per 21 CFR 314.50(d)(5)(vii)?				
If yes, date consult sent to the Controlled Substance Staff:				
For non-NMEs:				
<u>For non-NMEs</u> : Date of consult sent to Controlled Substance Staff:				
Date of consult sent to Controlled Substance Staff:	VES	NO	NA	Comment
Date of consult sent to Controlled Substance Staff: Pediatrics	YES	NO	NA	Comment PeRC meeting has
Date of consult sent to Controlled Substance Staff:	YES ×	NO	NA	Comment PeRC meeting has been scheduled for September 30, 2015.
Date of consult sent to Controlled Substance Staff: Pediatrics PREA			NA	PeRC meeting has been scheduled for

²

http://inside_fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/PediatricandMaternalHealthStaff/uc m027829 htm

(including new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration				
trigger PREA. All waiver & deferral requests, pediatric plans, and				
pediatric assessment studies must be reviewed by PeRC prior to				
approval of the application/supplement.				
If the application triggers PREA, is there an agreed Initial	\boxtimes			
Pediatric Study Plan (iPSP)?				
<i>If no, may be an RTF issue - contact DPMH for advice.</i> If required by the agreed iPSP , are the pediatric studies outlined	\boxtimes			
in the agreed iPSP completed and included in the application?				
in the agreed if of completed and mended in the appreation?				
If no, may be an RTF issue - contact DPMH for advice.				
BPCA:				
Is this submission a complete response to a pediatric Written		\boxtimes		
Is this submission a complete response to a pediatric Written				
Request?				
If yes, notify Pediatric Exclusivity Board RPM (pediatric				
exclusivity determination is required) ³				
Proprietary Name	YES	NO	NA	Comment
Is a proposed proprietary name submitted?	\boxtimes			
If yes, ensure that the application is also coded with the				
supporting document category, "Proprietary Name/Request for				
Review." REMS	YES	NO	NA	Comment
Is a REMS submitted?	ILS	\boxtimes	NA	Comment
Is a REIVIS submitted?				
If yes, send consult to OSE/DRISK and notify OC/				
OSI/DSC/PMSB via the CDER OSI RMP mailbox				
Prescription Labeling		ot appli	icable	
Check all types of labeling submitted.		ckage I		PI)
				Insert (PPI)
	Instructions for Use (IFU)			
	Medication Guide (MedGuide)			
	Carton labels			
	Immediate container labels			
	🗌 Di	luent		
	Ot Ot	her (sp	ecify)	
	YES	NO	NA	Comment
Is Electronic Content of Labeling (COL) submitted in SPL	\boxtimes			
format?				
If no, request applicant to submit SPL before the filing date.				

³

 $[\]underline{http://inside~fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/PediatricandMaternalHealthStaff/uc}{m027837~htm}$

Is the PI submitted in PLR format? ⁴					
If PI not submitted in PLR format, was a waiver or deferral requested before the application was received or in the submission? If requested before application was submitted, what is the status of the request? If no waiver or deferral, request applicant to submit labeling in					
PLR format before the filing date.					
For applications submitted on or after June 30, 2015: Is the PI submitted in PLLR format? ⁵			\boxtimes		
For applications submitted on or after June 30, 2015: If			\boxtimes		
PI not submitted in PLLR format, was a waiver or deferral					
requested before the application was received or in the					
submission? If requested before application was					
submitted, what is the status of the request?					
-					
If no waiver or deferral, request applicant to submit labeling in					
PLR/PLLR format before the filing date.					
All labeling (PI, PPI, MedGuide, IFU, carton and immediate	\boxtimes				
container labels) consulted to OPDP?					
MedGuide, PPI, IFU (plus PI) consulted to OSE/DRISK? (send WORD version if available)	\square				
Carton and immediate container labels, PI, PPI sent to OSE/DMEPA and appropriate CMC review office in OPQ (OBP or ONDP)?					
OTC Labeling		ot Appl	icable		
Check all types of labeling submitted.	Not Applicable Outer carton label Immediate container label Blister card Blister backing label Consumer Information Leaflet (CIL) Physician sample Consumer sample Other (specify)				
	YES	NO	NA	Comment	
Is electronic content of labeling (COL) submitted?					
If no, request in 74-day letter.					
Are annotated specifications submitted for all stock keeping units (SKUs)?			\boxtimes		

⁴

http://inside_fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/StudyEndpointsandLabelingDevelopmentTeam/ucm025576 htm

http://inside_fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/StudyEndpointsandLabelingDevelopmentTeam/ucm025576 htm

If no, request in 74-day letter.				
If representative labeling is submitted, are all represented			\boxtimes	
SKUs defined?				
If no, request in 74-day letter.				
All labeling/packaging sent to OSE/DMEPA?			\boxtimes	
Other Consults	YES	NO	NA	Comment
Are additional consults needed? (e.g., IFU to CDRH; QT	\boxtimes			QT-IRT 07/20/2015
study report to QT Interdisciplinary Review Team)				
If yes, specify consult(s) and date(s) sent:				
Meeting Minutes/SPAs	YES	NO	NA	Comment
Meeting Minutes/SPAs End-of Phase 2 meeting(s)?	YES	NO	NA	Comment
¥			NA	Comment
End-of Phase 2 meeting(s)?			NA	Comment
End-of Phase 2 meeting(s)?			NA	Comment
End-of Phase 2 meeting(s)? Date(s): 12/21/2012		NO	NA	Comment
End-of Phase 2 meeting(s)? Date(s): 12/21/2012 If yes, distribute minutes before filing meeting		NO	NA	Comment
End-of Phase 2 meeting(s)? Date(s): 12/21/2012 <i>If yes, distribute minutes before filing meeting</i> Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)? Date(s): 06/02/2014			NA	Comment
End-of Phase 2 meeting(s)? Date(s): 12/21/2012 If yes, distribute minutes before filing meeting Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)? Date(s): 06/02/2014 If yes, distribute minutes before filing meeting			NA	Comment
End-of Phase 2 meeting(s)? Date(s): 12/21/2012 If yes, distribute minutes before filing meeting Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)? Date(s): 06/02/2014 If yes, distribute minutes before filing meeting Any Special Protocol Assessments (SPAs)?			NA	Comment
End-of Phase 2 meeting(s)? Date(s): 12/21/2012 If yes, distribute minutes before filing meeting Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)? Date(s): 06/02/2014 If yes, distribute minutes before filing meeting			NA	Comment
End-of Phase 2 meeting(s)? Date(s): 12/21/2012 <i>If yes, distribute minutes before filing meeting</i> Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)? Date(s): 06/02/2014 <i>If yes, distribute minutes before filing meeting</i> Any Special Protocol Assessments (SPAs)? Date(s):			NA	Comment
End-of Phase 2 meeting(s)? Date(s): 12/21/2012 If yes, distribute minutes before filing meeting Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)? Date(s): 06/02/2014 If yes, distribute minutes before filing meeting Any Special Protocol Assessments (SPAs)?			NA	Comment

ATTACHMENT

MEMO OF FILING MEETING

DATE: August 3, 2015

BACKGROUND: On June 25, 2015, Pearl Therapeutics submitted a 505(b)(2) application for glycoyrrolate/formoterol inhalation aerosol with the proposed indication of COPD. The goal date is April 25, 2016.

REVIEW TEAM:

Discipline/Organization		Names	Present at filing meeting? (Y or N)
Regulatory Project Management	RPM:	Brandi Wheeler	Y
	CPMS/TL:	Ladan Jafari	Y
Cross-Discipline Team Leader (CDTL)			
Division Director/Deputy	Badrul Cho		Y
	Lydia Gilbe	rt McClain	Y
Office Director/Deputy			
Clinical	Reviewer:	Stacy Chin	Y
	TL:	Tony Durmowicz	Y
Social Scientist Review (for OTC products)	Reviewer:		
	TL:		
OTC Labeling Review (for OTC products)	Reviewer:		
	TL:		
Clinical Microbiology (for antimicrobial products)	Reviewer:		
	TL:		
Clinical Pharmacology	Reviewer:	Sheetal Agarwal	Y
	TL:	Suresh Doddapaneni	N
Genomics	Reviewer:		
Pharmacometrics	Reviewer:	Anshu Marathe	Y
Biostatistics	Reviewer:	Bob Abugov	Y
	TL:	David Petullo	N

Nonclinical (Pharmacology/Toxicology)	Reviewer:	Luqi Pei	Y
(TL:	Marcie Wood	Y
Statistics (carcinogenicity)	Reviewer:		
	TL:		
Product Quality (CMC) Review Team:	ATL:	Craig Bertha	Y
	RBPM:	Florence Aisida	Y
Drug Substance	Reviewer:	Ben Stevens	N
Drug Product	Reviewer:	Art Shaw	N
Process	Reviewer:	Brian Rogers	N
Microbiology	Reviewer:	Nutan Mytel	N
Facility	Reviewer:	Quallyna Porte	N
Biopharmaceutics	Reviewer:	Peng Duan	Y
Immunogenicity	Reviewer:	<u> </u>	
• Labeling (BLAs only)	Reviewer:		
• Other (e.g., Branch Chiefs, EA Reviewer)			
OMP/OMPI/DMPP (Patient labeling: MG, PPI, IFU)	Reviewer:	Nyedra Booker	Y
	TL:	Melissa Hulett	N
OMP/OPDP (PI, PPI, MedGuide, IFU, carton and immediate container labels)	Reviewer:	Roberta Szydlo	N
	TL:		
OSE/DMEPA (proprietary name, carton/container labels)	Reviewer:	Lissa Owens	N
,	TL:	Kendra Worthy	N
OSE/DRISK (REMS)	Reviewer:		
	TL:		
OC/OSI/DSC/PMSB (REMS)	Reviewer:		
	TL:		

Bioresearch Monitoring (OSI)	Reviewer:	Anthony Orencia	N
	TL:	Janice Pohlman	Y
Controlled Substance Staff (CSS)	Reviewer:		
	TL:		
Other reviewers/disciplines			
• Discipline	Reviewer:		
*For additional lines, highlight this group of cells, copy, then paste: select "insert as new rows"	TL:		
Other attendees	Nichelle Ra	ishid	Y
	Julia Pinto		Y
	Kelly Kitch	lens	Y
	Kassa Aya	lew	Y
	*For additional rows below"	lines, right click here and select "insert	

Т

FILING MEETING DISCUSSION:

GENERAL

GENEKAL	
• 505(b)(2) filing issues:	Not Applicable
 Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA? 	☐ YES ⊠ NO
 Did the applicant provide a scientific "bridge" demonstrating the relationship between the proposed product and the referenced product(s)/published literature? 	⊠ YES □ NO
Describe the scientific bridge (e.g., information to demonstrate sufficient similarity between the proposed product and the listed drug(s) such as BA/BE studies or to justify reliance on information described in published literature):	Pearl intends to reference NDA 17558 Robinul (glycopyrrolate) for PK and nonclinical data. The agency agreed that relative BA assessment was not needed because of large exposure margins.
• Per reviewers, are all parts in English or English translation?	⊠ YES □ NO
If no, explain:	
Electronic Submission comments	 ☐ Not Applicable ☑ No comments
List comments:	

CLINICAL	 ☐ Not Applicable ☑ FILE
	REFUSE TO FILE
Comments:	Review issues for 74-day letter
• Clinical study site(s) inspections(s) needed?	⊠ YES □ NO
If no, explain:	
Advisory Committee Meeting needed?	YES
Comments:	Date if known: NO To be determined
If no, for an NME NDA or original BLA, include the reason. For example:	Reason:
 this drug/biologic is not the first in its class the clinical study design was acceptable the application did not raise significant safety or efficacy issues 	
 the application did not raise significant public health questions on the role of the drug/biologic in the diagnosis, cure, mitigation, treatment or prevention of a disease 	
• If the application is affected by the AIP, has the division made a recommendation regarding whether or not an exception to the AIP should be granted to permit review based on medical necessity or public health significance?	 ☑ Not Applicable ☐ YES ☐ NO
Comments:	
 CONTROLLED SUBSTANCE STAFF Abuse Liability/Potential 	 Not Applicable FILE REFUSE TO FILE
Comments:	Review issues for 74-day letter
CLINICAL MICROBIOLOGY	 Not Applicable FILE REFUSE TO FILE
Comments:	Review issues for 74-day letter

CLINICAL PHARMACOLOGY	Not Applicable
	FILE
	□ REFUSE TO FILE
Comments:	Review issues for 74-day letter
• Clinical pharmacology study site(s) inspections(s)	YES
needed?	NO NO
BIOSTATISTICS	Not Applicable
	FILE
	REFUSE TO FILE
	Review issues for 74-day letter
Comments:	
NONCLINICAL	Not Applicable
(PHARMACOLOGY/TOXICOLOGY)	☐ Not Applicable ⊠ FILE
	\square REFUSE TO FILE
	Review issues for 74-day letter
Comments:	
PRODUCT QUALITY (CMC)	Not Applicable
	⊠ FILE
	🔲 REFUSE TO FILE
Comments:	Review issues for 74-day letter
New Molecular Entity (NDAs only)	
• Is the product an NME?	T YES
• Is the product an invite:	NO NO
Environmental Assessment	
Categorical exclusion for environmental assessment	⊠ YES
(EA) requested?	D NO
If no, was a complete EA submitted?	T YES
	□ NO
Comments:	
Facility Inspection	Not Applicable
• Establishment(s) ready for inspection?	YES
	□ NO
Commonte	
Comments:	

Facility/Microbiology Review (BLAs only)	Not Applicable
	☐ FILE
	□ REFUSE TO FILE
Comments:	Review issues for 74-day letter
CMC Labeling Review (BLAs only)	
Comments:	Review issues for 74-day letter
APPLICATIONS IN THE PROGRAM (PDUFA V)	N/A
(NME NDAs/Original BLAs)	
• Were there agreements made at the application's	☐ YES
pre-submission meeting (and documented in the	□ NO
minutes) regarding certain late submission	
components that could be submitted within 30 days	
after receipt of the original application?	
• If so, were the late submission components all	□ YES
submitted within 30 days?	\square NO
submitted within 50 days:	
• What late submission components, if any, arrived	
after 30 days?	
• Was the application otherwise complete upon	☐ YES □ NO
submission, including those applications where there were no agreements regarding late submission	
components?	
components:	
Is a comprehensive and readily located list of all	☐ YES
clinical sites included or referenced in the	□ NO
application?	
• Is a comprehensive and readily located list of all	YES
manufacturing facilities included or referenced in the	□ NO
application?	

	REGULATORY PROJECT MANAGEMENT
Signat	ory Authority: Badrul Chowdhury
Date o	f Mid-Cycle Meeting (for NME NDAs/BLAs in "the Program" PDUFA V): 11/16/2015
21 st Co option	entury Review Milestones (see attached) (listing review milestones in this document is al):
Comn	ients:
	REGULATORY CONCLUSIONS/DEFICIENCIES
	The application is unsuitable for filing. Explain why:
\boxtimes	The application, on its face, appears to be suitable for filing.
	<u>Review Issues:</u>
	 No review issues have been identified for the 74-day letter. Review issues have been identified for the 74-day letter.
	Review Classification:
	 Standard Review Priority Review
	ACTION ITEMS
	Ensure that any updates to the review priority (S or P) and classifications/properties are entered into the electronic archive (e.g., chemical classification, combination product classification, orphan drug).
	If RTF, notify everyone who already received a consult request, OSE PM, and RBPM
	If filed, and the application is under AIP, prepare a letter either granting (for signature by Center Director) or denying (for signature by ODE Director) an exception for review.
	If priority review, notify applicant in writing by day 60 (see CST for choices)
	Send review issues/no review issues by day 74
	Conduct a PLR format labeling review and include labeling issues in the 74-day letter
	Update the PDUFA V DARRTS page (for applications in the Program)
	Other

Annual review of template by OND ADRAs completed: September 2014

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRANDI E WHEELER 08/10/2015

LADAN JAFARI 08/10/2015

REGULATORY PROJECT MANAGER PHYSICIAN'S LABELING RULE (PLR) FORMAT REVIEW OF THE PRESCRIBING INFORMATION

Complete for all new NDAs, BLAs, Efficacy Supplements, and PLR Conversion Labeling Supplements

Application: 208294

Application Type: NDA

Name of Drug/Dosage Form: Glycopyrrolate and formoterol fumurate inhalation aerosol

Applicant: Pearl Therapeutics

Receipt Date: June 25, 2015

Goal Date: April 25, 2016

1. Regulatory History and Applicant's Main Proposals

Pearl Therapeutics submitted an NDA on June 25, 2015 for glycopyrrolate and formoterol fumurate inhalation aerosol with an indication of COPD.

2. Review of the Prescribing Information

This review is based on the applicant's submitted Word format of the prescribing information (PI). The applicant's proposed PI was reviewed in accordance with the labeling format requirements listed in the "Selected Requirements for Prescribing Information (SRPI)" checklist (see the Appendix).

3. Conclusions/Recommendations

SRPI format deficiencies were identified in the review of this PI. For a list of these deficiencies see the Appendix.

All SRPI format deficiencies of the PI will be conveyed to the applicant in the 74-day letter. The applicant will be asked to correct these deficiencies and resubmit the PI in <u>Word format</u> by September 18, 2015. The resubmitted PI will be used for further labeling review.

Appendix

The Selected Requirement of Prescribing Information (SRPI) is a 42-item, drop-down checklist of important <u>format</u> elements of the prescribing information (PI) based on labeling regulations (21 CFR 201.56 and 201.57) and guidances.

Highlights

See Appendix A for a sample tool illustrating the format for the Highlights.

HIGHLIGHTS GENERAL FORMAT

YES 1. Highlights (HL) must be in a minimum of 8-point font and should be in two-column format, with ¹/₂ inch margins on all sides and between columns.

<u>Comment</u>:

NO 2. The length of HL must be one-half page or less unless a waiver has been granted in a previous submission. The HL Boxed Warning does not count against the one-half page requirement. Instructions to complete this item: If the length of the HL is one-half page or less, select "YES" in the drop-down menu because this item meets the requirement. However, if HL is longer than one-half page, select "NO" unless a waiver has been granted.

Comment: Sponsor has submitted waiver

- YES 3. A horizontal line must separate HL from the Table of Contents (TOC). A horizontal line must separate the TOC from the FPI.
 Comment:
- NO 4. All headings in HL must be **bolded** and presented in the center of a horizontal line (each horizontal line should extend over the entire width of the column as shown in Appendix A). The headings should be in UPPER CASE letters.

Comment: Lines should be extended over entire width of column

YES 5. White space should be present before each major heading in HL. There must be no white space between the HL Heading and HL Limitation Statement. There must be no white space between the product title and Initial U.S. Approval. See Appendix A for a sample tool illustrating white space in HL.

Comment:

YES
 6. Each summarized statement or topic in HL must reference the section(s) or subsection(s) of the Full Prescribing Information (FPI) that contain more detailed information. The preferred format is the numerical identifier in parenthesis [e.g., (1.1)] at the end of each summarized statement or topic.

Comment:

YES 7. Section headings must be presented in the following order in HL:

Section	Required/Optional
Highlights Heading	Required
 Highlights Limitation Statement 	Required
Product Title	Required
 Initial U.S. Approval 	Required

Boxed Warning	Required if a BOXED WARNING is in the FPI
Recent Major Changes	Required for only certain changes to PI*
 Indications and Usage 	Required
 Dosage and Administration 	Required
 Dosage Forms and Strengths 	Required
Contraindications	Required (if no contraindications must state "None.")
Warnings and Precautions	Not required by regulation, but should be present
Adverse Reactions	Required
Drug Interactions	Optional
 Use in Specific Populations 	Optional
Patient Counseling Information Statement	Required
Revision Date	Required

* RMC only applies to the BOXED WARNING, INDICATIONS AND USAGE, DOSAGE AND

ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS AND PRECAUTIONS sections.

<u>Comment</u>:

HIGHLIGHTS DETAILS

Highlights Heading

8. At the beginning of HL, the following heading must be **bolded** and should appear in all UPPER CASE letters: "HIGHLIGHTS OF PRESCRIBING INFORMATION".
 <u>Comment</u>:

Highlights Limitation Statement

YES
 9. The bolded HL Limitation Statement must include the following verbatim statement: "These highlights do not include all the information needed to use (insert name of drug product) safely and effectively. See full prescribing information for (insert name of drug product)." The name of drug product should appear in UPPER CASE letters.

Comment:

Product Title in Highlights

YES 10. Product title must be **bolded**.

Comment:

Initial U.S. Approval in Highlights

YES 11. Initial U.S. Approval in HL must be **bolded**, and include the verbatim statement "**Initial U.S. Approval:**" followed by the **4-digit year**.

<u>Comment</u>:

Boxed Warning (BW) in Highlights

YES 12. All text in the BW must be **bolded**.

Comment:

YES 13. The BW must have a heading in UPPER CASE, containing the word "WARNING" (even if more than one warning, the term, "WARNING" and not "WARNINGS" should be used) and other words to identify the subject of the warning (e.g., "WARNING: SERIOUS INFECTIONS and ACUTE HEPATIC FAILURE"). The BW heading should be centered.

Comment:

YES 14. The BW must always have the verbatim statement "*See full prescribing information for complete boxed warning*." This statement should be centered immediately beneath the heading and appear in *italics*.

Comment:

YES 15. The BW must be limited in length to 20 lines (this includes white space but does not include the BW heading and the statement "*See full prescribing information for complete boxed warning.*").

Comment:

Recent Major Changes (RMC) in Highlights

 N/A 16. RMC pertains to only the following five sections of the FPI: BOXED WARNING, INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS AND PRECAUTIONS. RMC must be listed in the same order in HL as the modified text appears in FPI.

Comment:

N/A
 17. The RMC must include the section heading(s) and, if appropriate, subsection heading(s) affected by the recent major change, together with each section's identifying number and date (month/year format) on which the change was incorporated in the PI (supplement approval date). For example, "Warnings and Precautions, Acute Liver Failure (5.1) --- 9/2013".

Comment:

N/A 18. The RMC must list changes for at least one year after the supplement is approved and must be removed at the first printing subsequent to one year (e.g., no listing should be one year older than revision date).

Comment:

Indications and Usage in Highlights

YES 19. If a product belongs to an established pharmacologic class, the following statement is required under the Indications and Usage heading in HL: "(Product) is a (name of established pharmacologic class) indicated for (indication)".

Comment:

Dosage Forms and Strengths in Highlights

N/A 20. For a product that has several dosage forms (e.g., capsules, tablets, and injection), bulleted subheadings or tabular presentations of information should be used under the Dosage Forms and Strengths heading.

Comment:

Contraindications in Highlights

YES 21. All contraindications listed in the FPI must also be listed in HL or must include the statement "None" if no contraindications are known. Each contraindication should be bulleted when there is more than one contraindication.

Comment:

Adverse Reactions in Highlights

YES 22. For drug products other than vaccines, the verbatim **bolded** statement must be present: "To report SUSPECTED ADVERSE REACTIONS, contact (insert name of manufacturer) at (insert manufacturer's U.S. phone number) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch".

Comment:

Patient Counseling Information Statement in Highlights

YES 23. The Patient Counseling Information statement must include one of the following three **bolded** verbatim statements that is most applicable:

If a product **does not** have FDA-approved patient labeling:

• "See 17 for PATIENT COUNSELING INFORMATION"

If a product has FDA-approved patient labeling:

- "See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling"
- "See 17 for PATIENT COUNSELING INFORMATION and Medication Guide" <u>Comment</u>:

Revision Date in Highlights

YES 24. The revision date must be at the end of HL, and should be **bolded** and right justified (e.g., "**Revised:** 9/2013").

Comment:

Contents: Table of Contents (TOC)

See Appendix A for a sample tool illustrating the format for the Table of Contents.

YES 25. The TOC should be in a two-column format.

<u>Comment</u>:

YES 26. The following heading must appear at the beginning of the TOC: "FULL PRESCRIBING INFORMATION: CONTENTS". This heading should be in all UPPER CASE letters and bolded.

Comment:

YES 27. The same heading for the BW that appears in HL and the FPI must also appear at the beginning of the TOC in UPPER CASE letters and **bolded**.

<u>Comment</u>:

YES 28. In the TOC, all section headings must be **bolded** and should be in UPPER CASE.

<u>Comment</u>:

NO 29. In the TOC, all subsection headings must be indented and not bolded. The headings should be in title case [first letter of all words are capitalized except first letter of prepositions (through), articles (a, an, and the), or conjunctions (for, and)].

<u>Comment</u>: Subsection headings are bolded. Additional periods after subsection 13.1.

YES 30. The section and subsection headings in the TOC must match the section and subsection headings in the FPI.

<u>Comment</u>:

YES 31. In the TOC, when a section or subsection is omitted, the numbering must not change. If a section or subsection from 201.56(d)(1) is omitted from the FPI and TOC, the heading "FULL PRESCRIBING INFORMATION: CONTENTS" must be followed by an asterisk and the following statement must appear at the end of TOC: "*Sections or subsections omitted from the full prescribing information are not listed." *Comment:*

Full Prescribing Information (FPI)

FULL PRESCRIBING INFORMATION: GENERAL FORMAT

YES 32. The bolded section and subsection headings in the FPI must be named and numbered in accordance with 21 CFR 201.56(d)(1) as noted below (section and subsection headings should be in UPPER CASE and title case, respectively). If a section/subsection required by regulation is omitted, the numbering must not change. Additional subsection headings (i.e., those not named by regulation) must also be bolded and numbered.

BOXED WARNING
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
6 ADVERSE REACTIONS
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Labor and Delivery
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
9 DRUG ABUSE AND DEPENDENCE
9.1 Controlled Substance
9.2 Abuse
9.3 Dependence
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
12.4 Microbiology (by guidance)
12.5 Pharmacogenomics (by guidance)
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2 Animal Toxicology and/or Pharmacology
14 CLINICAL STUDIES
15 REFERENCES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

<u>Comment</u>:

YES 33. The preferred presentation for cross-references in the FPI is the <u>section</u> (not subsection) heading followed by the numerical identifier. The entire cross-reference should be in *italics* and enclosed within brackets. For example, "*[see Warnings and Precautions (5.2)]*" or "*[see Warnings and Precautions (5.2)]*".

Comment:

N/A 34. If RMCs are listed in HL, the corresponding new or modified text in the FPI sections or subsections must be marked with a vertical line on the left edge.

Comment:

FULL PRESCRIBING INFORMATION DETAILS

FPI Heading

YES 35. The following heading must be **bolded** and appear at the beginning of the FPI: "FULL **PRESCRIBING INFORMATION".** This heading should be in UPPER CASE.

<u>Comment</u>:

BOXED WARNING Section in the FPI

YES 36. In the BW, all text should be **bolded**.

<u>Comment</u>:

YES 37. The BW must have a heading in UPPER CASE, containing the word "WARNING" (even if more than one Warning, the term, "WARNING" and not "WARNINGS" should be used) and other words to identify the subject of the Warning (e.g., "WARNING: SERIOUS INFECTIONS and ACUTE HEPATIC FAILURE").

<u>Comment</u>:

CONTRAINDICATIONS Section in the FPI

N/A 38. If no Contraindications are known, this section must state "None."

<u>Comment</u>:

ADVERSE REACTIONS Section in the FPI

YES 39. When clinical trials adverse reactions data are included (typically in the "Clinical Trials Experience" subsection of ADVERSE REACTIONS), the following verbatim statement or appropriate modification should precede the presentation of adverse reactions:

"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice."

Comment:

N/A 40. When postmarketing adverse reaction data are included (typically in the "Postmarketing Experience" subsection of ADVERSE REACTIONS), the following verbatim statement or appropriate modification should precede the presentation of adverse reactions:

"The following adverse reactions have been identified during post-approval use of (insert drug name). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure."

Comment:

PATIENT COUNSELING INFORMATION Section in the FPI

N/A 41. Must reference any FDA-approved patient labeling in Section 17 (PATIENT COUNSELING INFORMATION section). The reference should appear at the beginning of Section 17 and

include the type(s) of FDA-approved patient labeling (e.g., Patient Information, Medication Guide, Instructions for Use).

Comment:

YES 42. FDA-approved patient labeling (e.g., Medication Guide, Patient Information, or Instructions for Use) must not be included as a subsection under section 17 (PATIENT COUNSELING INFORMATION). All FDA-approved patient labeling must appear at the end of the PI upon approval.

Comment:

Appendix A: Format of the Highlights and Table of Contents

HIGHLIGHTS OF PRESCRIBING INFORMATION	CONTRAINDICATIONS
These highlights do not include all the information needed to use [DRUG	• [text]
NAME] safely and effectively. See full prescribing information for	• [text]
[DRUG NAME].	
	WARNINGS AND PRECAUTIONS
[DRUG NAME (nonproprietary name) dosage form, route of	• [text]
administration, controlled substance symbol]	• [text]
Initial U.S. Approval: [year]	
	ADVERSE REACTIONS
WARNING: [SUBJECT OF WARNING]	Most common adverse reactions (incidence $> x\%$) are [text].
See full prescribing information for complete boxed warning.	
	To report SUSPECTED ADVERSE REACTIONS, contact [name of
• [text]	manufacturer] at [phone #] or FDA at 1-800-FDA-1088 or
• [text]	www.fda.gov/medwatch.
DESERVE & LOD STRAND	DRUG INTERACTIONS
RECENT MAJOR CHANGES	• [text]
[section (X.X)] [m/year]	• [text]
[section (X.X)] [m/year]	VOL IN ORCHERC ROBULATIONS
INDICATIONS AND USACE	USE IN SPECIFIC POPULATIONS
INDICATIONS AND USAGE	• [text]
[DRUG NAME] is a [name of pharmacologic class] indicated for [text]	• [text]
DOSAGE AND ADMINISTRATION	
	See 17 for PATIENT COUNSELING INFORMATION [and FDA-
• [text]	approved patient labeling OR and Medication Guide].
• [text]	Device de fun (men)
DOGLOF FORMS AND STRENGTIC	Revised: [m/year]
DOSAGE FORMS AND STRENGTHS	
[text]	
[text]	9 DRUG ABUSE AND DEPENDENCE
[text] FULL PRESCRIBING INFORMATION: CONTENTS*	9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING]	
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE	9.1 Controlled Substance
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION	9.1 Controlled Substance 9.2 Abuse
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text]	9.1 Controlled Substance9.2 Abuse9.3 Dependence
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text]	9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text]	9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS	9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text]	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacodynamics 12.4 Microbiology 12.5 Pharmacogenomics
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text]	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text]	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacodynamics 12.3 Pharmacodynamics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacodynamics 12.3 Pharmacodynamics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 [text]
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS 7.1 [text]	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacodynamics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 [text] 14.2 [text]
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS 7.1 [text] 7.2 [text] 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacodynamics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 [text] 14.2 [text] 15 REFERENCES
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS 7.1 [text] 7.2 [text] 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnacy 8.2 Labor and Delivery	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacodynamics 12.3 Pharmacodynamics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 [text] 14.2 [text] 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS 7.1 [text] 7.2 [text] 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnacy 8.2 Labor and Delivery 8.3 Nursing Mothers	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacodynamics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 [text] 14.2 [text] 15 REFERENCES
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS 7.1 [text] 7.2 [text] 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 [text] 14.2 [text] 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 2.2 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS 7.1 [text] 7.2 [text] 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnacy 8.2 Labor and Delivery 8.3 Nursing Mothers	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 [text] 14.2 [text] 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not
[text] FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: [SUBJECT OF WARNING] 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 [text] 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 [text] 5.2 [text] 6 ADVERSE REACTIONS 6.1 [text] 6.2 [text] 7 DRUG INTERACTIONS 7.1 [text] 7.2 [text] 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use	 9.1 Controlled Substance 9.2 Abuse 9.3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 [text] 14.2 [text] 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRANDI E WHEELER 08/10/2015

LADAN JAFARI 08/10/2015